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ABSTRACT 
Local Health Departments (LHDs) are critical providers of Human Immunodeficiency Virus (HIV) and 
sexually transmitted infection (STI) prevention efforts. HIV Pre-Exposure Prophylaxis (PrEP) is an 
evolving public health initiative and practitioners should consider PrEP interventions in context of ethical 
decision-making and a broad STI prevention strategy as global incidence of bacterial STIs remains high 
and those at-risk for HIV are generally at-risk for other STIs. An evaluation of the Thinking Ethically 
framework and LHD PrEP services was performed to fill a gap in the literature and support program 
decision-making. A retrospective review of PrEP user medical records from a LHD in north Georgia from 
July 2019 to June 2020 was performed and data were assessed using descriptive statistics, negative 
binomial, and logistic regression. Total STI tests performed by the LHD from July 2018 to June 2020 
were calculated to determine the change in STI testing services associated with the onset of the COVID-
19 pandemic. The Thinking Ethically framework was valuable to PrEP-related decision-making. There 
were 63 PrEP users in the study period of which most were White non-Hispanic (60.3%) men who have 
sex with men (61.9%). Retention in care was associated with clinic site. Most bacterial STI cases 
diagnosed among PrEP users were asymptomatic (75%). Fifty percent of PrEP users obtained services 
beyond STI prevention including vaccination and referrals. District STI testing declined between the 
second quarter of 2020 and 2019 with a decline in HIV testing by 38%, syphilis by 48%, gonorrhea and 
chlamydia by over 50%. LHD decision-makers can feasibly apply the Thinking Ethically framework to 
public health practice. Results support the need for LHD continuous quality management as retention in 
care differed by clinic site, and more resources will be needed to engage hard-to-reach populations at-risk 
for HIV like injection drug users. The COVID-19 pandemic impacted PrEP and STI services and more 
data is needed to determine the long-term effects of the COVID-19 pandemic on the STI landscape. 
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Statement of the Problem 
Local Health Departments (LHDs) are critical providers of population-level Human 
Immunodeficiency Virus (HIV) and sexually transmitted infection (STI) prevention efforts and can 
significantly impact provision and access to HIV Pre-exposure Prophylaxis (PrEP) services.1 PrEP 
is the administration of antiretroviral therapy (ART) combined with behavioral counseling for 
primary prevention of HIV.1,2 Public health practitioners should consider multiple ethical principles 
to maximize PrEP and STI prevention resources for the greatest population-level benefit in the 
context of a broad STI prevention strategy.3,4 Practitioners can elicit consideration of multiple 
ethical principles with use of the Thinking Ethically decision-making framework when deliberating 
decisions of ethical consequence5 like whether to provide PrEP services or how best to optimize 
limited resources. PrEP is an evolving public health initiative and public health practitioners should 
weigh factors including biomedical risks, access disparities, and risk behavior with available 
resources when implementing PrEP interventions.3,4 However, limited data on LHD PrEP 
provision, program impact, and program evaluation is available to guide decision-makers.6 Data 
evaluating LHD PrEP intervention outcomes in suburban and rural LHDs in the Southeast US, an 
area with significant STI and HIV disease burden, is a current gap in the literature.  
HIV incidence in 2018 was 11.4 per 100,000 population (about 40,000 cases per year) in 
the United States (US) and disparities in incidence exist.2,7 Total HIV incidence in the US declined 
from 2008 to 2018, but incidence has remained steady or increased among racial minorities 
including Black and Latino men who have sex with men (MSM).2,7 PrEP has demonstrated 
tolerability and effectiveness as HIV prevention when administered as directed with up to 99% 
efficacy against sexual transmission of HIV in at-risk groups.2,8 Medications used for PrEP are 
generally well-tolerated and adverse events have included gastrointestinal discomfort, nausea, 
8 
 
decrease in bone mineral density and renal function, hepatitis B flare, and HIV viral resistance.2 
Benefits of PrEP have included reduced fear of HIV and feelings of empowerment surrounding 
sexual health among PrEP users.9  
 Public health practitioners should consider PrEP interventions in context of a broad STI 
prevention strategy as global incidence of bacterial STIs (gonorrhea, chlamydia, syphilis) remains 
high, and those at-risk for HIV are generally at-risk for other STIs.10,11 STI resistance is increasing, 
and complications of STIs can include pain, infertility, neurological and cardiovascular disease.10,11 
STI prevention strategies should consider behavioral and pathogen-specific factors including social 
networks, prevention fatigue, condom use, and probability of transmission as bacterial STI 
infection can increase the risk of HIV acquisition.12 Data associating PrEP use with increased risk 
behavior has been mixed and increased STI incidence among PrEP cohorts may be attributed to 
preexisting increases in STI trends, selection bias, or increased screening which can facilitate 
timely diagnosis and treatment.10,11 
 Public health practitioners must allocate finite resources with consideration to available 
resources, cost, risk, and populations most at-risk for HIV.13,14 LHDs at the forefront of the 
COVID-19 pandemic response (ongoing at the time of this writing) must also allocate resources to 
support existing programs in addition to COVID-19 testing, syndromic surveillance, contact 
tracing, and vaccination campaigns. US PrEP-to-need analysis of 2017 fourth-quarter data was 
remarkable for disparities between those most at-risk and those receiving PrEP as those at-risk 
living in the South and non-Medicaid expansion states were less likely to receive PrEP relative to 
need.15 PrEP can be efficient and cost-saving if those most at-risk are prioritized, but allocating 
resources for PrEP should be weighed against the impact of enhancing HIV treatment efforts and 
the burden of HIV in the target area.13,14 HIV viral control among people living with HIV (PLWH) 
through use of ART is considerably effective at reducing the spread of HIV.2 Clinical capacity can 
impact the feasibility of proving PrEP as providing condoms requires less clinical capacity than 
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oral PrEP, and oral PrEP is expected to require less clinical capacity than future injectable Long-
Acting PrEP (LA PrEP).16 Provider uptake and provision of oral PrEP has been generally slow due 
to multiple factors including knowledge, awareness, and stigma.17 High attrition with PrEP use has 
also been appreciated.18  
Purpose of the Study 
The purpose of this study was to perform a program evaluation of LHD PrEP services in 
the North Georgia Health District (NGHD) between July 2019 and June 2020. Outcomes included 
PrEP user demographics; length of time users are enrolled in the program; diagnosis of HIV, 
gonorrhea, chlamydia, syphilis among PrEP users; and description of services provided to PrEP 
users beyond STI prevention. The study was framed through the Thinking Ethically framework to 
guide future LHD STI prevention efforts and PrEP-related decision-making.  
This study also provided a unique opportunity to study LHD PrEP services and STI 
testing over the period that included the onset of the COVID-19 pandemic. The COVID-19 
pandemic impacted NGHD clinical services during the study period, but this study was not planned 
to investigate the impact of COVID-19 on LHD PrEP and STI care. To encourage social 
distancing, the NGHD reduced PrEP and STI services and ceased nonessential in-person 
encounters for all programs in the second quarter of 2020. Quarterly total of HIV, gonorrhea, 
chlamydia, and syphilis tests performed in NGHD clinic sites from July 2017 to June 2020 were 
assessed to quantify the degree of NGHD STI service changes associated with the onset of the 
COVID-19 pandemic. Assessing total number of performed STI tests from July 2017 to June 2020 
served to provide NGHD leadership with baseline data to determine when district STI services 
return to pre-pandemic quantity. 
Research Questions 




2. Did NGHD PrEP services reach those most at-risk for HIV in the district? 
3. How long did PrEP users stay in the program? 
4. What additional services were provided to PrEP users beyond STI prevention?  
5. How many asymptomatic bacterial STIs were diagnosed among PrEP users? 
6. How much did NGHD STI testing change in the period associated with the onset of the 
COVID-19 pandemic? 
Delimitations 
The study was conducted via a retrospective chart review of NGHD PrEP users between 
July 2019 and June 2020, the first year NGHD district-wide PrEP services were provided. Only 
those receiving PrEP from the NGHD were included in the study. Those living within the NGHD 
but receiving PrEP from providers unaffiliated with the NGHD were excluded. Only those with 
STIs diagnosed by NGHD study sites were included in STI assessments. Those living within the 
NGHD but diagnosed with STIs by providers unaffiliated with the NGHD were excluded. 
Definition of Terms 
Antiretroviral Therapy (ART) – medication active against HIV used as prevention among those at-
risk and treatment among those living with HIV 
HIV Pre-Exposure Prophylaxis (PrEP) – prescribed antiretrovirals for primary prevention of HIV 
LHD – Local Health Department 
MSM – Men who have sex with men including gay, bisexual, and other men who have sex with 
men 
North Georgia Health District (NGHD) – a local health district in north Georgia in the southeastern 
United States and site of data collection for this study 
PLWH – People living with HIV 
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PWID – People who use injection drugs 
Risk Compensation – increase in behavior that increases risk of STI acquisition due to perceived 
protection from HIV due to PrEP use 
Sexually Transmitted Infection (STI) – for purpose of this study, STI generally refers to HIV, 
gonorrhea, chlamydia, and syphilis 
Treatment as Prevention (TasP) – prescribed antiretrovirals for people living with HIV to 








Thinking Ethically about HIV 
 Public health decision-making is complex, and practitioners must consider conflicting 
values and ethical considerations when making decisions at the population level.3,19 The field of 
public health ethics emerged in the 1990s in response to population-level ethical concerns that 
could not be adequately addressed through bioethical principles during the HIV epidemic.19,20 
Bioethical principles of autonomy, beneficence, nonmaleficence, and justice are largely focused on 
the individual and often used in research and clinical medicine but have been inadequate to fully 
address community concerns of individual versus community rights, health promotion, and 
resource allocation.19,20 Public health ethics must balance the values of individuals with community 
well-being, recognizing that what is in the best interest of the individual is not always in the best 
interest of the community.19  
 The HIV epidemic in the 1990s had a profound impact on public health ethics as medical 
providers, policymakers, and public health professionals confronted significant ethical questions 
regarding individual versus community rights, allocation of resources, access to care, individual 
privacy, and presence of social health disparities.20 Decision-makers were forced to confront social 
issues like discrimination, fear and stigma, and balance individual liberty, dignity and health for 
those most affected.20 Medical advances surrounding HIV and antiretroviral therapy (ART) have 
significantly altered the contemporary public health HIV decision-making landscape, but ethical 
dilemmas still exist.3 Public health practitioners must determine how to allocate finite resources to 
benefit the most people while striving to reduce health disparities as HIV often impacts vulnerable 
and socially disenfranchised groups.3 
 In 2012, the World Health Organization (WHO) held a multidisciplinary assembly of 
international stakeholders including scientists, ethicists, policy-makers, human rights and HIV 
13 
 
community advocates to discuss the ethical considerations of ART use in HIV prevention.3 ART 
use in HIV prevention can be prescribed for people living with HIV (PLWH) as Treatment as 
Prevention (TasP) or those of negative HIV status as Pre-Exposure Prophylaxis (PrEP); TasP and 
PrEP are both effective prevention strategies.3 The assembly discussed that public health 
practitioners will need to use multiple, and potentially conflicting, ethical principles in ART-related 
decision-making, and more attention should be provided to social and policy barriers impacting 
HIV.3  Decisions will widely vary based on community-level epidemiology, available resources, 
and sociopolitical climates as those most at-risk for HIV and sexually transmitted infections (STIs) 
are often disenfranchised and face barriers related to the social determinants of health.3 Principles 
used in HIV-related decision-making can include utility (prioritizing interventions with the greatest 
net benefit), equity (prioritizing interventions that reduce health disparities), urgent need 
(prioritizing treatment of the sickest), rule of rescue (prioritizing treatment for those at imminent 
risk of death), and prioritarianism (prioritizing the least advantaged).3 
 In the context of HIV, use of ethical principles in decision-making can yield different 
results depending on the frame of reference.3 An intervention chosen using the utility principle can 
be perceived to produce the most benefit if it prioritizes PLWH or those of HIV negative status and 
if it benefits the largest number of people or those most at-risk, but a strict utility focus on 
benefiting the greatest number of people can also result in health disparities.3 Decisions made using 
the equity principle are reasonable in principle as it is generally agreed that people should have fair 
access to health resources although equity is difficult to achieve in practice due to real-world 
resource limitations.3 Furthermore, equity priorities can conflict between prioritizing health status 
or health access.3 Principles like urgent need, rule of rescue, and prioritarianism generally prioritize 
those of worst health status which conflict with the principle of utility because prioritizing those 
most affected can result in fewer resources available for the greater population.3 It can also be 
difficult to determine those of worst health or highest-risk in context of HIV because HIV burden is 
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closely intertwined with social determinants of health.3 Highest-risk can be interpreted as most at-
risk of death from HIV, most at-risk of acquiring HIV, and most vulnerable from low 
socioeconomic status.3  
 HIV-related public health decision-making should generally seek to identify local 
priorities to guide fair distribution of resources, maximize population-level benefit, and base 
program decisions on data-supported evidence.3 Optimal solutions will vary and must acknowledge 
social and political limitations including stigma, discrimination, and illegal nature of some HIV-
associated risk factors (like injection drug use or sex work).3 HIV prevention should also be 
considered in context of a comprehensive STI prevention strategy due to significant disease 
burden, increasing STI incidence, shared prevention strategies and shared risk factors between HIV 
and non-HIV STIs.10,11,21 
 Thinking Ethically is a framework created by Velasquez et al5 at the Markkula Center for 
Applied Ethics as a method to identify ethical considerations and apply ethical decision-making to 
practice.5 The framework was chosen for its design as an applied framework, stepwise approach to 
ethical decision-making, and use of multiple ethical principles which is in accordance with the 
WHO recommendation to assess PrEP and HIV prevention from multiple ethical perspectives.3,5 
The framework provides a series of steps to gather data and evaluate available options from 
multiple ethical approaches to achieve the best course of action.5 After recognizing an ethical issue, 
practitioners should gather relevant data about the issue including relevant stakeholders and options 
for acting.5 Practitioners should then evaluate each option through the perspective of five different 
ethical approaches, the utilitarian, rights, justice, common good, and virtue approach.5  
 The utilitarian approach emphasizes the action that provides the most benefit and least 
harm to all those affected by an action.5 The rights approach emphasizes the moral rights of 
individuals which are numerous and have included autonomy, dignity, truth, privacy, and to not be 
injured.5 The justice approach emphasizes fairness and equal treatment of those affected by an 
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action.5 The common good approach emphasizes community welfare and prioritizes the community 
benefit of an action with attention to those most vulnerable and is suited to evaluate policy and 
public health.5 The virtue approach emphasizes actions that align with virtuous character traits like 
honesty, courage, tolerance, compassion, integrity, prudence and self-control.5 Velasquez et al5 
provided a series of questions intended to elicit the perspective of each approach: 
• Which option will produce the most good and do the least harm? (The utilitarian approach)  
• Which option best respects the rights of all who have a stake? (The rights approach)  
• Which option treats people equally or proportionately? (The justice approach)  
• Which option best serves the community as a whole, not just some members? (The 
common good approach)  
• Which option leads me to act as the sort of person I want to be? (The virtue approach)5 
After working through each question, practitioners should then consider all approaches, 
reflect on or hypothetically test the decision, implement the decision, and reflect upon the decision 
outcome.5 Velasquez et al5 discussed that ethics is a way people should act and is not a science, 
religion, law, cultural norm, or set of feelings.5 There is significant room for debate in ethical 
decision-making, but the best action is often identified as ideal through multiple ethical 
approaches.5 Thinking Ethically principles (justice, utility, rights, common good, and virtue) were 
used to frame the research questions of this study. 
STI and HIV Disease Burden 
There are over 30 different pathogens known to be sexually transmitted.22 STIs have a 
substantial worldwide disease burden and STI incidence has been increasing.11,21,23 The WHO has 
estimated that global STI acquisition is over one million cases per day with an annual incidence of 
over 350 million cases per year of one of the four common curable STIs (chlamydia, gonorrhea, 
syphilis or trichomoniasis).11,22 STI public health practice considerations include newly recognized 
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STIs (Zika, hepatitis, Ebola virus), drug resistance (resistant gonorrhea), risk behavior (recreational 
drug use, risk compensation associated with antiretroviral success), commercial sex and sexual 
violence.21 Generally, bacteria and parasite STIs cause acute symptoms while viral STIs cause 
chronic infections.21 STI complications can include infertility, pain, neurological and 
cardiovascular complications (syphilis), cancer (human papillomavirus), liver disease (hepatitis A 
and B), and death (HIV).11,21,23 Common curable STIs (chlamydia, gonorrhea, and syphilis) are 
often asymptomatic leading to delayed screening, diagnosis and treatment.21–23 STI related tissue 
impairment also increases risk of HIV acquisition.11,21–23 
Those most at-risk for STIs and HIV in the US include those living in southern states, 
youth, MSM, racial minorities and those of low socioeconomic status.7,23 US STI incidence has 
been increasing, and youth age 15 to 24 years accounted for about half of STI diagnosis in 2018.23 
From 2017 to 2018, chlamydia, gonorrhea and syphilis incidence increased among males and 
females of all ethnic groups in all regions of the US.23 In 2018, chlamydia was the most reported 
notifiable infectious disease with a disease burden of 539.3 cases per 100,000 population, a 2.9% 
increase from 2017.23 Gonorrhea was the second most reported notifiable infectious disease with a 
5% increase from 2017. Syphilis incidence was 115,045, the highest since 1991 and a 13.3% 
increase from 2017.23 In 2018, primary and secondary (P&S) syphilis were predominantly 
identified among MSM (53.5%), PLWH (41.6%), and women (14.2%).23 Women are an emerging 
risk-group for syphilis; from 2017 to 2018, a 30.4% increase in P&S syphilis incidence was 
appreciated among women which is concerning for maternal transmission and congenital syphilis.23 
In 2018, incidence of chlamydia and gonorrhea was highest among US states in the South, and 
incidence of syphilis was highest among states in the West followed by states in the South.23 
Global HIV mortality and morbidity have made significant advances since the 1990s.24 
Global HIV mortality peaked in 2004-2005 with over two million deaths worldwide and declined 
to 1.1 million deaths in 2015.24 HIV incidence peaked in 1997 with an estimated 3.5 million 
infections per year and declined to 2.1 million in 2015.24 Global HIV prevalence has also declined 
17 
 
since 2001, and study of prevalence must take into account that PLWH are now living longer due 
to advances in ART efficacy, tolerability, and access.24  
The impact of advances in ART efficacy, tolerability, and access on global HIV mortality 
and incidence are considered significant public health successes.24,25 Trends in life expectancy of 
PLWH have increased in all parts of the globe although disparities in access to HIV testing and 
treatment still exist and high-income countries have appreciated the most gain.25 In 2012, the life 
expectancy of PLWH in Canada was about 90% of those of negative HIV status while the life 
expectancy of PLWH in Rwanda was about 60% of those of negative HIV status.24,25 In Canada, 
the life expectancy of a 20-year-old living with HIV compared to those of negative HIV status 
increased from 50.7% in 2000-2003 to 89.1% in 2008-2012.25 PLWH who continue ART and 
maintain HIV viral suppression also have virtually no risk of transmitting HIV to others (Treatment 
as Prevention).26 The current Joint United Nations Programme on HIV/AIDS (UNAIDS) global 
ending HIV epidemic campaign, 90-90-90, targets for 90% of PLWH to know their status, 90% of 
those to receive sustained ART, and 90% of those to achieve sustained HIV viral suppression.24 
The current US Department of Health and Human Services (HHS) ending the HIV epidemic 
campaign, Ending the HIV Epidemic: A Plan for America, targets a 75% reduction in new HIV 
infections by 2025 and 90% reduction by 2030 through sustained HIV viral suppression among 
90% of PLWH in the US and prevention strategies including PrEP and syringe services programs 
for people who use injection drugs (PWID).27 
In the US, PLWH are generally older while populations most at-risk for new diagnosis 
include youth, MSM, PWID, racial minorities, those of low socioeconomic status and in southern 
states.7 In 2017, there were 1,003,782 known PLWH in the US with a prevalence rate of 308.7.7 
Those aged 50-54 (767.8) were the largest group of PLWH followed by 55-59 (660.6).7 Rates of 
new HIV diagnoses have generally declined since 2013 however disparities among at-risk groups 
exist and incidence has increased among some sub-populations.2,7 In 2018, the age group with the 
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highest HIV incidence was among those 25 to 29 years (32.5) followed by 20-24 years (27.6).7 
HIV incidence by race was highest among Black/African American (39.3) followed by 
Hispanic/Latino (16.2).7 In 2018, males accounted for 81% of diagnoses and the most significant 
risk factors were MSM (70%) followed by PWID.7 South US states continued to have the highest 
incidence (15.7) compared to the Northeast (10.0), West (9.3), and Midwest (7.2).7  
In 2017, Georgia ranked first among US states in HIV incidence among adults and 
adolescents and fourth in HIV prevalence.28 At-risk groups for HIV in Georgia mirror those of the 
US with Black/Non-Hispanic, youth and MSM at highest risk.28 The North Georgia Health District 
(NGHD), a largely suburban and rural area, includes two counties identified among the 220 most 
vulnerable counties in the US for rapid transmission of HIV and hepatitis C due to injection drug 
use in a 2016 assessment by the Centers for Disease Control and Prevention (CDC).29,30 In 2017, 
NGHD youth had the highest incidence of HIV and PLWH were generally older, which is 
consistent with the state and national profile, but racial and ethnic group HIV incidence and 
prevalence differed from the state and national data as most PLWH in the NGHD were White/Non-
Hispanic.28 In 2017, NGHD HIV incidence was largest among White/Non-Hispanic (50%) 
followed by Hispanic (21.4%), and Black/Non-Hispanic (17.9%) with the largest number of new 
diagnosis occurring among youth age 20-29 (39.3%).28 In 2017, PLWH in the NGHD were largely 
White/Non-Hispanic (57.2%) followed by Black/Non-Hispanic (19.4%) and Hispanic (15.7%), and 
predominantly adults age 30-39 (18.9%), 40-49 (24.8%), and 50-59 (29.2%).28  
Structural Factors Associated with STI Risk 
 The HIV and STI epidemic is well-established as interwoven with social determinants of 
health: genetic and individual factors alone cannot account for the significant discrepancy in HIV 
and STI risk among low income and minority populations.31,32 Multiple studies assessing HIV and 
syndemic risk (accumulated risk of two or more factors that work synergistically) with intersecting 
negative social, behavioral, and structural factors have been performed.33 Those most at-risk for 
STIs (youth, racial and ethnic minorities, people of low socioeconomic status, MSM, and PWID) 
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often face multiple syndemic risk factors, and global and national prevention efforts have 
emphasized the importance of targeting social determinants of health in HIV prevention since the 
1990s.31–34 Syndemic HIV and STI risk factors have included social instability, homelessness, 
unemployment, low education level, poverty, stigma, discrimination, trauma, incarceration, drug 
use, geographic location and limited healthcare access.31,33,34  
 A cross-sectional and longitudinal analysis comparing gonorrhea incidence to 
socioeconomic status by decennial census tract (1990 and 2000) in New York state (excluding New 
York City) between 1992-1993 and 2001-2002 found geographic associations between areas of low 
socioeconomic status and gonorrhea incidence, and changes in gonorrhea incidence were 
associated with changes in socioeconomic status.35 Study modeling demonstrated that a 5% 
increase in census tract poverty rate was associated with an 8% increase in gonorrhea incidence 
(relative risk 1.08).35 Multivariate modeling of census tract, gonorrhea incidence, and race were 
remarkable for increased gonorrhea incidence disparities among non-Hispanic Blacks in areas 
where non-Hispanic Blacks were less than 10% of the population.35 In areas with less than 10% 
non-Hispanic Blacks, a 5% change in poverty rate was associated with a 23% increase in gonorrhea 
incidence among Black residents compared to areas with over 10% non-Hispanic Blacks where a 
significant change in gonorrhea incidence was not appreciated.35  
 Minority populations in the US, like Black and Latinos, encounter disparities in virtually 
all social determinants of health including poverty, racism, trauma, incarceration, and substance 
use compared to Whites.33 According to the 2010 US census, Blacks had the highest rate of poverty 
followed by Hispanics and Whites.33 Blacks and Latinos have been more likely to experience 
individual and systematic racism compared to Whites including residential segregation, 
environmental health stress, community violence, criminal justice discrimination, and live in a 
resource-poor area.33 MSM, bisexual, and transgender individuals have faced additional stress of 
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homophobia and gender-related stigma or abuse which increases the risk of depression and 
condomless sex.33,36  
Systematic racism and stigma limit the social and political capital of minority communities 
and increase the risk of psychological conditions and sexual risk behavior that subsequently 
increase the risk of HIV, particularly among minority youth and transgender individuals.33,36 
Research on HIV risk, childhood and adolescent sexual abuse and trauma (a known risk factor for 
increased risk behavior and condomless sex) since the 1990s has demonstrated higher rates of 
sexual and physical abuse among Black and Hispanic MSM compared to Whites.33 In 2003, US 
Blacks were more likely to be incarcerated (1 in 8) compared to Latinos (1 in 27) and Whites (1 in 
63).33 Racial and ethnic minorities have also been more likely to experience substance abuse 
disorders, initiate injection drug use in adolescence, experience addiction, relapse after substance 
use treatment, and receive less substance use treatment compared to Whites.33  
Illicit Drug Use and STI Risk 
Illicit drug use has been increasing in the US and is strongly associated with high-risk 
sexual behavior including multiple partners and condomless sex.37 Opioids include drugs like 
prescription opioids, heroin, synthetic and illicitly manufactured opioids (like illicitly manufactured 
fentanyl).37,38 In 2017, 67.8% of the 70,237 drug overdose deaths in the US were opioid-related and 
the number of synthetic opioid-related deaths in the US increased by 45.2% from 2016 to 2017.38 A 
recent cross-sectional community-based survey study investigating the intersection between 
lifetime STI diagnosis, illicit drug and opioid use in Alachua County, Florida (a county with STI 
rates higher than the state and national average) found that 204 (9.3%) of 2,194 survey respondents 
age 18 to 50 years self-reported ever having an STI, of which, 74.2% reported any illicit drug use, 
69.6% reported marijuana use, and 52.5% reported opioid use.37 Those self-reporting an STI were 




 STI prevention programs that include content on alcohol and illicit drug use have 
demonstrated greater efficacy compared to those without alcohol and illicit drug content.39 A 
cluster randomized clinical trial comparing the impact of STI prevention programs with content on 
sexual risk reduction only; sexual risk reduction and alcohol; and sexual risk reduction, alcohol, 
and marijuana on STI incidence at 12-months after completion of the STI prevention program 
found the lowest STI incidence among those in the sexual risk reduction, alcohol and marijuana 
group.39 The study included 460 adolescents at an adolescent detention center from 2010 to 2014, 
of which 361 presented for a 12-month follow-up.39 At 12 month follow-up, 3.9% of the sexual risk 
reduction, alcohol and marijuana group; 10.2% of the sexual risk reduction and alcohol group; and 
12.4% of the sexual risk reduction group were diagnosed with an STI of which chlamydia (79.6%) 
and gonorrhea (13.6%) were the most common.39 
 STI prevention efforts among drug users should be tailored to the population as 
differences in HIV risk behavior by gender and drug use have been appreciated although data on 
gender-based differences in number of partners, condomless sex, and sex exchange among drug 
users has been mixed.40 A survey assessing gender-based HIV risk among 1,429 drug users in 
multisite drug treatment programs across the US in 2007 was remarkable for overall increased 
sexual behavior risk among women drug users compared to men.40 Women were more likely to 
have multiple partners (20% versus 13%) and no gender difference in unprotected sex or sex 
exchange was appreciated.40 Men were more likely to use injection drugs (32% versus 24%) and no 
gender difference in needle sharing was appreciated.40 Women who used alcohol were 1.11 times 
more likely to have risky sex behavior compared to men.40 Women who had greater psychiatric 
comorbidities were 1.14 times more likely to engage in risky sex behavior compared to men.40 
Participants (male and female) who used stimulant illicit drugs were 1.57 times more likely to 
engage in risky sex behavior than those who did not use stimulants.40 Participants (male and 
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female) who reported history of sexual abuse were 4.1 times more likely to engage in risky sex 
behavior compared to those without history of sexual abuse.40 
Crisis and STI Risk 
The 2020 COVID-19 pandemic is a significant factor impacting data collected in this study 
as global social distancing drastically changed global economic and social behavior during this 
study period. It was assumed that STI incidence during the pandemic declined due to reduced 
screening (the study sites postponed or limited PrEP and STI care during the COVID-19 pandemic) 
or due to an actual reduction in incidence related to social distancing. The long-term effects of 
COVID-19 on mental health, economics, and STI incidence are not yet known, and this study 
provided a unique assessment of LHD STI incidence surrounding a global pandemic in the 
Southeast US. Previous data has supported increased STI incidence and STI-associated risk 
behavior surrounding periods of political, environmental, and socioeconomic crisis like the 
September 11, 2001 attack and the 2008 Financial Crisis.41–44  
A retrospective chart review of 3,520 PrEP users from January and April 2020 in Boston, 
Massachusetts to assess the impact of COVID-19 on PrEP care found the number of clients 
initiating PrEP fell by 72% (from 122 per month in January to 34 per month in April 2020).45 The 
number of PrEP prescription refill lapses increased (140 in January to 407 in April) with youth, 
racial minorities, and those with public versus private insurance more likely to have a lapse in PrEP 
refill.45 Screening for gonorrhea and chlamydia also declined by 85% between January and April.45 
A separate internet survey of 1,051 MSM in the United States to investigate the impact of COVID-
19 on sexual health in April 2020 found that 51.3% reported fewer sex partners during the COVID-
19 pandemic, 47.6% reported no change in number of sex partners, and 0.9% reported increased 
number of sex partners, 92.9% reported no change in condom use, and 68% reported reduced 
opportunities to have sex.46 When asked about adherence to local COVID-19 social distancing 
stay-at-home orders, 20.1% reported 100% adherence, 71.4% reported between 50% and 100% 
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adherence, and 8.5% reported less than 50% adherence. When asked about life impact, 19.1% 
reported losing their job, 72.7% reported increased anxiety, 14.8% reported being food insecure 
within the last 12 months, 9.9% reported increased use of recreational drugs, and 26% reported 
increased use of alcohol.46  
A 2002 internet survey of 2,915 MSM investigating sex and drug behavior three months 
before and after the September 11 attack found that drinking until drunk, condomless anal sex, and 
number of partners increased among those who reported death of a family member or friend in the 
attack (n=329) compared to those reporting seeing the attack in person (n=104) or living within a 
10 mile radius of the World Trade Center or Pentagon (n=35).41 Participants reported similar levels 
of drinking until drunk, condomless sex, and number of partners before the attack.41 After the 
attack, the adjusted odds ratio of drinking until drunk, increased condomless sex, and increased 
number of partners among those reporting a death was 1.41, 1.44, and 1.94; witnessing the attack in 
person was 1.04, 1.14, and 0.74; and living within 10 miles of the attack site was 0.87, 0.73, and 
1.72 respectively.41  
A survey of Manhattan residents in New York found that cigarette, alcohol and marijuana 
use were increased at one (n=988) and six months (n=854) after the September 11 attack.42 At six 
months, average reported consumption of cigarettes increased by 103.8 cigarettes per month 
(median of 30), alcohol increased by 17.7 drinks per month (median of 9), and occurrence of 
marijuana use increased by 7.6 incidents per month (median of 2).42 Survey respondents who 
reported psychological or posttraumatic stress symptoms were more likely to report increased 
substance use, and a reduction of psychological stress symptoms at six months was not associated 
with a reduction in drug use.42 The authors discussed that the addictiveness of drugs may prolong 
changes in drug use beyond the initial stress response to a traumatic event.42  
A study assessing adherence to HIV treatment among MSM enrolled in the Protease 
Inhibitor Longitudinal Life Study (ongoing in the time surrounding the September 11 attack) found 
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a significant increase in missed or suboptimal ART doses immediately following the September 11 
attack.47 Of 300 study participants, 68 were found to have sufficient adherence data before and after 
the attack.47 In a 14-day period, the cohort missed an average of 2.67 ART doses before and 5.07 
ART doses after the attack and reported late ART administration (four or more hours off schedule) 
an average of 2.34 doses before and 4.34 doses after the attack.47 ART adherence is essential to 
HIV TasP and suboptimal ART adherence can increase the risk of HIV transmission.26 
Data has also demonstrated increased infectious disease and STI incidence during 
economic crisis as periods of individual stress can increase high-risk behavior and reduced 
spending often leads to fewer available resources for disease prevention, screening, and 
treatment.43,44 Areas of Eastern Europe and the former Soviet Union experienced a severe economic 
crisis in the 1990s as average gross domestic product fell by about one-third, and rates of HIV and 
Tuberculosis increased during that time (Tuberculosis incidence almost tripled in Russia).44 
Increases in disease burden outlasted the economic crisis and some areas of eastern Europe and the 
former Soviet Union were unable to reverse or halt the spread of HIV and Tuberculosis over a 
decade later.44 A systematic review of 37 studies on the impact of economic crisis on infectious 
disease found 30 studies that identified worsening disease outcomes during periods of crisis, and 
few studies identified positive outcomes including healthcare reform triggered by deteriorating 
disease control during the economic crisis.44 A study assessing STI diagnosis during the 2008 
global financial crisis via retrospective review of 1,437 medical records in an STI treatment clinic 
in Granada, Spain demonstrated an increase in STI diagnoses from 56.6% in the non-crisis period 
(2000-2007) to 75.2% in the crisis period (2008-2014).43 STIs diagnosed in the crisis and non-crisis 
periods were human papillomavirus (n=103 and 69), candida (n=22 and 37), molluscum 
contagiosum (n=18 and 14), gardnerella (n=13 and 8), syphilis (n=13 and 10), gonorrhea (n=12 and 
10), HIV (n=6 and 5), and trichomoniasis (n=1 and 3).43 
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Protective Factors Reducing STI Risk 
Protective factors against HIV and STI acquisition can be social, behavioral, and 
structural.33,34 Reduced HIV risk has been associated with structural factors like the availability of 
social welfare programs for finance, education, housing, and medical assistance; community 
factors like neighborhood cohesion and social capital; and individual psychological resilience like 
adaptive coping, empowerment, and self-efficacy.33 National and community public health 
interventions in the US have generally attempted to reduce structural health disparities with policy, 
legal action, and funding through initiatives like social welfare programs, legal action against 
discrimination, and appropriation of funding to community organizations working to improve 
economic and educational disparities.32,33 An ecological study of 66 metropolitan areas in the US 
from 2003 to 2015 found lower rates of STIs among women in states with higher minimum wage.48 
A one-dollar adjusted increase in minimum wage was associated with a 19.7% decrease in syphilis 
and 8.5% decrease in gonorrhea among women.48 Minimum wage increase was not associated with 
a change in chlamydia rates.48 Confounding variables and limitations in this study exist; however, 
data has supported that presence or absence of social welfare policies are associated with 
population STI risk.48 
At the individual level, condoms remain the primary public health prevention strategy 
against multiple STIs with well documented clinical and cost-effectiveness.49–51 Condom nonuse is 
the most significant risk factor for STI acquisition, and condoms have demonstrated low failure 
(breakage or slippage) rates in vaginal and anal sex.49–51 STI acquisition risk also depends on 
number of exposures, disease-specific infectivity, and probability of condom failure.49 Condoms 
are more likely to be effective in preventing STIs transmitted through body fluids (HIV, chlamydia, 
and gonorrhea) than direct skin contact (syphilis) and disease-specific condom effectiveness has 
been appreciated.49 With condom use in vaginal intercourse, gonorrhea infectivity has been 
estimated at about 0.20 in men and 0.50 in women, syphilis infectivity has been estimated at about 
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0.30, and average HIV infectivity has been estimated to be about 0.001.49 HIV infectivity is 
variable depending on an individual’s HIV viral load and low estimated average HIV infectivity 
has been attributed to lower transmission risk among those adherent to ART with suppressed HIV 
(Treatment as Prevention).49  
 Numerous studies regarding sexual behavior and condom use were collected in the 1990s 
and data from this time strongly supported the use of condom subsidies to increase condom uptake 
after cost was determined to be a significant barrier to condom acquisition in the US.52 A 1999 
study comparing condom uptake and longitudinal survey data during a state-wide free condom 
distribution campaign and reduced cost (25 cents) condom distribution campaign in Louisiana 
found that condom distribution significantly declined when the price of condoms increased from 
free to 25 cents.52 In the state-wide free condom campaign, condoms were distributed to state-
funded health clinics and over 1,000 businesses in areas with high rates of STIs including 
convenience stores, salons, motels, and liquor stores with an average of 200,381 condoms 
distributed per month state-wide.52 After condom cost increased from free to 25 cents, state-wide 
condom distribution reduced to 2% of the free condom volume with an average of 4,217 condoms 
distributed per month.52 Consumers at 195 of the businesses receiving free condoms were surveyed 
on condom uptake and use when condoms were free (time 1), three months after condom price 
increased to 25 cents (time 2), and nine months after the first survey (time 3).52 Survey data 
demonstrated a reduction in condom uptake after the price of condoms increased.52 When condoms 
were free (time 1), 57% reported obtaining condoms of which 77% used condoms during their 
most recent sexual encounter.52 When condoms were 25 cents (time 3), 30% reported obtaining 
condoms of which 64% used condoms during their most recent sexual encounter.52 
A meta-analysis of structural condom interventions from 1998-2007 found that condom 
uptake was increased through interventions that improved condom accessibility and availability 
among multiple high-risk groups.53 Effective interventions included free condom distribution, 
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social marketing to increase condom use, and improving in-store condom visibility.53 A recent 
assessment of retail barriers to purchasing condoms in Atlanta, Georgia, an urban area in the 
Southeast US at high-risk for STIs, found that environmental and physical barriers to purchasing 
condoms exist.54 Few stores sold condoms relative to population in the most populated areas of the 
city (one store per about 7,000 people), 80% of stores required interaction with retail associates to 
access condoms, and 28% of stores kept condoms out of sight below the checkout counter.54 The 
authors discussed that at-risk populations may experience embarrassment requesting assistance 
from retail clerks when purchasing condoms, and environmental changes to increase condom 
uptake can include improved retail visibility, installation of condom vending machines, self-
checkout, and online ordering.54 
Sexual Risk Behavior and Behavior Change 
A significant body of literature on risk behavior and HIV prevention has been developed 
since the 1980s, and behavior modification and condom use were the foundation of HIV prevention 
for the first 30 years of the HIV epidemic before significant biomedical advances like TasP and 
PrEP were available.14,55 HIV and STI prevention behavior modification interventions are typically 
founded in social science behavior change theory like theory of reasoned action, theory of planned 
behavior, and social cognitive theory and generally attempt to reduce individual risk-taking 
behavior (reduced condomless sex, number of sex partners, drug use or needle sharing) by 
modifying a risk factor or determinant.55,56 Risk determinants are numerous and have included 
individual and systematic factors.56 Individual risk determinants and have included attitude, 
knowledge, self-efficacy, depression, childhood abuse, substance use, interpersonal and behavioral 
skills, perception of risk and HIV severity, and perception that behavior change is feasible, 
desirable and controlled by the individual.55,56 Systematic factors associated with sexual risk 
behavior have included discrimination, cultural norms, and socioeconomic status.55,56 
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A meta-analysis of 194 HIV-related behavior change interventions from 1985 to 2003 
found that interventions that focused on attitude, education, behavior and interpersonal skills were 
most effective, and interventions that encouraged active participation (like role-playing condom 
negotiation and client-centered counseling) were more effective than those using only passive 
techniques (like watching educational videos).55 Intervention impact depended on participant 
characteristics including age, gender, risk group, ethnicity, and past condom use.55 Youth were 
more impacted by normative social pressure, men often had more control on condom use than 
women, and interventions with MSM were generally more effective than those with women or 
PWID.55 Interventions based on the information-motivation-behavioral skills model attempted to 
change social norms, perceptions of behavioral control and vulnerability to HIV, and were effective 
only when paired with behavior skills training (like carrying condoms and negotiating condom use 
with partners).55 Fear-based interventions were less successful than interventions based on 
motivational and cognitive empowerment and could be counter-productive.55  
Individual sexual behavior has also been considered complex to study due to the intimate 
nature of sex, involvement of another individual, and presence of multiple associated individual 
and systematic factors that can be difficult or unethical to control with experimental study design.56 
A systematic review assessing longitudinal and experimental studies on HIV prevention, sexual 
risk behavior and psychosocial variables from 1991 to 2014 found that temporal data on 
associations between sexual risk behavior and behavior risk determinants have been mixed.56 
Among 44 longitudinal studies, 44.3% assessed sexual risk behavior of MSM, and the most 
consistent factors with a longitudinal association on condomless sex were depression, substance 
use, childhood sexual abuse, and having a previously diagnosed STI although the direction of 
correlation was mixed.56 Among nine experimental studies, experiment induced changes in self-
efficacy, sex norms and expectations had mixed results on behavior change.56 Experiment induced 
changes in knowledge had no significant effect.56 The authors discussed that theoretical and 
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associated sexual behavior risk factors are significant despite a lack of experimental data due to the 
complexity of assessing sexual behavior as some factors (like sexual abuse or discrimination) 
cannot ethically be induced in a controlled experimental setting.56  
Most data on sexual behavior change and STI incidence among PrEP users have been 
collected in clinical trial or open-label settings, like iPrEX, iPERGAY and the PROUD trial.10,57 
Data demonstrating increased STI incidence among PrEP users has been largely consistent, data on 
presence of behavior change has been mixed, and data collected in clinical trial or open-label 
settings and may not be generalizable to community-based settings.10,57 A longitudinal cohort study 
assessing sexual behavior and condom use among 183 MSM PrEP users in a public health 
community-based STI clinic in Seattle, Washington from October 2014 to April 2017 found that 
the number of condomless sexual encounters increased and about half of PrEP users were 
diagnosed with a bacterial STI during the first year of PrEP use.57 In this cohort, 13.8% reported 
condomless sex before starting PrEP, 22% reported condomless sex at nine months of PrEP use, 
and 16% reported condomless sex at 12 months of PrEP use.57 The average STI diagnosed per 
person was 0.5 before starting PrEP and 1.1 in the first year after starting PrEP although it is not 
clear if this increase in STI incidence was due to behavior change or increased screening.57 Number 
of partners, number of partners living with HIV, and sexual position (insertive or receptive) did not 
significantly change throughout the first year.57  
A study of community-based PrEP users in the community-based Kaiser medical system in 
San Francisco from 2012 to 2015 assessed STI incidence among 657 PrEP users and behavior 
change among 143 survey respondents.58 The study included 388 person-years of PrEP use and the 
average length of PrEP use was 7.2 months.58 No new HIV diagnoses were appreciated among 657 
PrEP users during the study period, 30% were diagnosed with a non-HIV STI within the first six 
months, and 50% were diagnosed with a non-HIV STI within the first 12 months.58 In this cohort, 
143 PrEP users completed a survey on sexual behavior with 76% reporting no change in number of 
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sex partners, 56% reporting no change in condom use, and 41% reporting decreased condom use.58 
The researchers were unable to identify factors associated with increased number of partners or 
reduced condom use and considered no new HIV diagnosis to be significant.58 The researchers 
estimated that, in absence of PrEP, HIV incidence in this population would have been as high as 
8.9 per 100 person-years based on data from a previously performed delayed-PrEP study arm with 
similar STI incidence.58  
A study assessing bacterial STI incidence of 280 PrEP users at an outpatient center in New 
York by screening for bacterial STIs at 3-month intervals instead of 6-months intervals as 
recommended by current CDC clinical PrEP guidelines found 21% of PrEP users were diagnosed 
with a bacterial STI within the 6 months before starting PrEP, 11% were diagnosed on their initial 
PrEP visit, 13% were diagnosed at 3-month follow-up, and 15% were diagnosed at 9-month 
follow-up.59 Ten percent of all bacterial STIs diagnosed in the study period were asymptomatic and 
identified by routine STI screening, 77% of those diagnosed at 3-month screening and 68% of 
those diagnosed at 9-month screening were asymptomatic.59 The authors discussed that 24% of the 
cohort would have had delayed bacterial STI diagnosis and treatment if 3-month screening had not 
been performed, and more frequent STI screening may benefit timely bacterial STI diagnosis and 
treatment.59 
Behavior Risk Optimism and Risk Compensation 
Studies in the 1990s and 2000s on risk optimism, an optimistic feeling about HIV risk due 
to advances in HIV treatment, and increases in sexual risk behavior demonstrated consistent 
associations between risk perceptions and behavior.56,60 Most data from that time attributed 
increased sexual risk behavior to risk optimism although one cross-sectional and longitudinal study 
using survey data of MSM age 18 to 27 from 1998/1999 (n=538) and 2000/2001 (n=275) found 
that HIV treatment optimism did not predict risk behavior but risk behavior did predict HIV 
treatment optimism.60 These results were inconsistent with the mainstream assumption of 
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perception-behavior temporality.60 The researchers suggested that HIV treatment optimism may be 
a rationalization after participation in condomless sex or risky sexual behavior and discussed the 
need for additional study to determine causality.60 Furthermore, confounding variables that could 
increase sexual risk behavior at that time included emerging personal use of the internet and 
recreational drugs like amphetamines and sildenafil (brand name Viagra), released in 1998.60 
Contemporary STI-associated sexual risk behaviors are consistent with those over the last 30 years 
and include internet use with mobile dating apps and recreational drug use associated with 
addiction or mental health conditions like anxiety or depression.21 
Risk compensation, an increase in risky sexual behavior due to perceived protection, was 
historically credited for increased STI incidence among women after the advent of oral 
contraceptives and in the 1990s among those presenting for HIV care.61 Risk compensation in the 
context of PrEP is generally defined as a change in behavior that increases risk of STIs due to 
perceived protection from HIV including reduced condom use or increase in number of sex 
partners.10,21,57 Data attributing PrEP user STI incidence increase to risk compensation has been 
mixed.10 Risk compensation has been used by some providers and decision-makers to explain a 
global increase in non-HIV STI incidence and justify withholding PrEP.21,62 Conversely, others 
have disputed the significance of risk compensation in global STI incidence trends arguing that 
PrEP-eligible individuals are generally considered to be at higher risk for STIs and increases in STI 
incidence can be attributed to selection bias, preexisting trends, or increased STI screening among 
PrEP users compared to non-users.10,61,62 PrEP advocates argue that an association between PrEP 
and behavior change does not undermine the impact of PrEP on HIV prevention, and support PrEP 
as a part of a comprehensive STI prevention strategy that includes sexual behavior risk 
counseling.62  
Qualitative interviews of 14 PrEP using MSM in Seattle, Washington found that 
commonly stated reasons for not using condoms were perceptions that condoms reduced 
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spontaneity, were awkward to use, reduced physical sensation, and reduced intimacy.63 Many 
respondents perceived PrEP as a safety measure to offset a preference for condomless sex or self-
recognized pattern of condomless sex behavior despite an intention to use condoms.63 Qualitative 
interviews with 30 PrEP using MSM in San Francisco, California revealed reduced condom use 
among 73% of respondents, 40% continued to use condoms with new partners, 16.7% reduced 
condom use with partners who were also taking PrEP, and 13.3% reported condomless sex after 
starting PrEP and resumed condom use after being diagnosed with a non-HIV STI.64 Participants 
also reported reduced condom use due to feeling protected from HIV or during periods of drug use 
that altered decision-making.64 In the Seattle and San Francisco study, respondents who 
consistently used condoms reported fear of non-HIV STIs as reason for continued condom use.63,64 
HIV and STI Prevention by Abstinence 
 Abstinence from sexual behavior is a clear way to prevent STIs, but abstinence education 
as a public health strategy has been ineffective at preventing STIs and teenage pregnancy despite 
support from the US federal government and many US states.65 Two systematic reviews performed 
by the Community Preventative Service Taskforce, a nonfederal body that provides data to inform 
public health policy and decision-making in the US, found insufficient evidence to support 
abstinence education programs, and sufficient evidence to support comprehensive sexual risk-
reduction education as a public health strategy to reduce sexual risk behavior and prevent 
pregnancy and STIs among middle and high school-age adolescents.66 A comparison of US state 
school sex education policies in 2005 found that states with policies emphasizing abstinence 
education had worse teenage pregnancy rates compared to those providing education on abstinence, 
contraception, and condom use.65 States placing more emphasis on abstinence were also more 
likely to have residents living in poverty and higher degree of religiosity than those with more 
comprehensive sex education programs.65 
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HIV Prevention by Treatment as Prevention 
 Treatment as Prevention (TasP) is a strategy to reduce HIV transmission through early 
initiation and consistent use of ART by PLWH.26,67–69 TasP is effective to prevent HIV by 
suppressing HIV viral replication in sites of HIV transmission including blood, tissues and 
secretions of the genital tract.26 A landmark study in 2011, HTPN052, demonstrated that early ART 
initiation reduced HIV transmission among serodiscordant couples (one negative partner and one 
partner living with HIV) by 96%.26,67–69 This scientific breakthrough led to a change in global HIV 
treatment and prevention strategies to initiate ART among all PLWH regardless of CD4 and 
immune status.26,69 Subsequent TasP studies (PARTNER, Opposites Attract, and PARTNER2) 
demonstrated even superior results.68 The current US Health and Human Services core HIV 
prevention message states People Living With HIV who are undetectable or virally suppressed 
have effectively no risk of spreading HIV to their HIV negative sexual partners.68 Current global 
HIV treatment and prevention strategies emphasize the importance of TasP along with other 
prevention measures including behavior modification, condom use, and PrEP.69  
 ART tolerability and availability have significantly improved since the completion of the 
first triple-drug therapy studies in 1996.24 Reduced global HIV incidence has coincided with global 
scale-up of ART provision and access throughout the 2010s.26 In 2010, WHO guidelines reserved 
ART for those with late-stage HIV (CD4 less than 350 cells/mm3), landmark studies demonstrating 
improved HIV treatment outcomes and TasP with earlier ART initiation were completed shortly 
after (HTPN052 TasP study in 2011), and WHO guidelines changed to support universal ART 
(providing ART to every PLWH regardless of CD4 count) by 2016.26,67 
 PLWH must maintain consistent ART use to sustain HIV viral suppression, and ART 
should be initiated early in HIV infection for optimal TasP as people with acute or early HIV 
infection have been estimated to be over 20 times more likely to transmit HIV than those with 
established infection.26 Those with acute HIV (two to four weeks after infection) are known to have 
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the highest HIV viral load (amount of circulating HIV) increasing risk of HIV transmission.70 After 
the acute phase, HIV viral load declines and gradually increases over time in absence of ART 
(chronic HIV infection).70 End-stage HIV occurs after about 10 years in absence of ART; is 
characterized by CD4 below 200 cells/mm3, presence of opportunistic infection, and high HIV viral 
load that again increases the risk of HIV transmission.70 Data on the long-term impact of acute HIV 
infection on population-level incidence has been mixed and PLWH of all stages can transmit HIV 
without consistent ART use.26,70 
 Supporting ART adherence is essential for optimal HIV treatment outcomes, HIV 
suppression (HIV viral load below 200 copies of viral RNA per mL of serum) and TasP.26,68,71 In 
2015, CDC national HIV surveillance estimated that 60% of all PLWH in the US were virally 
suppressed, 80% of PLWH engaged in HIV treatment were virally suppressed, and two of three 
PLWH sustained HIV viral suppression for one year.68 In the US, the Health Resources and Service 
Administration’s (HRSA) public health Ryan White HIV/AIDS Program has provided treatment 
and support services to over 50% of PLWH in the US and uses a variety of social support services 
in attempt to reduce treatment disparities.71 In the US, disparities in ART access, adherence and 
TasP remain among youth, Blacks, women, transgender, and housing insecure populations.71 From 
2010 to 2016, national Ryan White HIV/AIDS Program HIV viral suppression increased from 
69.5% to 84.9% among all clients.71 Disparities in HIV viral suppression also declined from 2010 
to 2016 between Black and White clients (13% to 8.1%), male and transgender clients (9% to 6%), 
male and female clients (5% to 1%), and those age 13 to 24 (youth) and 55 to 64 (33% to 20%).71 
Continued reduction of ART disparities is essential to ending the HIV epidemic.71 
HIV Prevention by HIV Pre-Exposure Prophylaxis 
ART use for PrEP in the US was FDA approved in July 2012 and provides an opportunity 
for at-risk groups to engage in clinical care, receive risk-reduction counseling and STI screening.2,61 
PrEP is recommended for sexually active individuals at-risk for HIV including those who are not in 
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a monogamous relationship with an HIV negative partner, those with recent STI diagnosis, and 
PWID.2 Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC, brand name Truvada) and 
tenofovir alafenamide/emtricitabine (TAF/FTC, brand name Descovy), a combination of two 
nucleoside reverse transcriptase inhibitors, are the predominant medications used for PrEP in the 
US and are up to 99% effective at preventing HIV through sexual transmission when taken daily as 
directed.2,72,73 Event-driven (on-demand or 2-1-1 PrEP) is the use of PrEP on days of and 
immediately following sex and is not currently recommended by the CDC.2  
Event-driven PrEP is recommended as an alternative schedule by the WHO for MSM who 
find less than daily dosing more convenient, have sex less than twice per week on average, and can 
postpone sex for two hours after initiating event-driven PrEP.74 Event-driven PrEP is administered 
with a loading dose (two pills) 2 to 24 hours before sex, another dose (one pill) 24 hours after the 
first dose, and a final dose (one pill) 48 hours after the first dose (hence the description, “2-1-1 
PrEP”).74 If event-driven PrEP users continue to have sex after the initial loading dose, they should 
continue to take one pill daily as long as sex continues and for two days after the last sexual 
encounter.74 Event-driven PrEP is not recommended for women, transgender women on estrogen, 
transgender men having vaginal sex, men who have sex with women, or people with chronic 
hepatitis B infection.74 There is limited data on event-driven PrEP efficacy in non-MSM 
populations with data suggesting tenofovir (TDF) may be less concentrated in the female genital 
tract and less effective when administered with estrogen.74 A study of TDF/FTC drug levels in 
transgender women on feminizing hormones found that TDF/FTC did not affect hormone levels, 
but hormones decreased tenofovir plasma levels by 13% which does not reduce daily PrEP efficacy 
but may reduce efficacy of event-driven PrEP.74  
Tenofovir/emtricitabine is generally well-tolerated.2 Nausea is the most common side-
effect, present in less than 10% of users, and is often self-limiting within the first month of use.2 
Adverse reactions to tenofovir/emtricitabine can include decreased bone mineral density, renal 
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insufficiency, hepatitis B flare, and HIV viral resistance.2 Older adults and those with preexisting 
renal disease are more at-risk for tenofovir/emtricitabine-associated renal impairment.58 
tenofovir/emtricitabine is active against hepatitis B and irregular dosing or abrupt cessation can 
increases risk for hepatitis B flare and subsequent liver impairment in those with chronic hepatitis 
B infection.2 Hepatitis B is a vaccine-preventable illness transmitted through sex or blood contact 
and has shared risk factors with HIV including injection drug use and multiple sex partners.75  
Most cases of HIV viral resistance among PrEP users have been attributed to inappropriate 
initiation of PrEP in individuals living with HIV who should have initiated HIV treatment instead 
because tenofovir/emtricitabine alone is inadequate for HIV treatment.2 Observed HIV mutations 
among PrEP users have included K65R and M184V conferring resistance to nucleoside reverse 
transcriptase inhibitors tenofovir and emtricitabine respectively.2 Those who acquired HIV after 
PrEP initiation were less likely to develop HIV viral resistance but rare transmission of 
tenofovir/emtricitabine-resistant virus has been reported.2,76 Overall risk of HIV resistance among 
PrEP users remains low when PrEP is used as directed.2 
Long-Acting PrEP (LA PrEP) is an emerging PrEP delivery system currently in Phase III 
clinical trials administered via injection every two to three months with two drugs, cabotegravir (an 
integrase inhibitor) and rilpivirine (a non-nucleoside reverse transcriptase inhibitor).16,72 In clinical 
trials, LA PrEP has been generally well tolerated with the most common side-effect of pain and 
redness at the injection site.16 LA PrEP has the potential to improve PrEP adherence by reducing 
daily pill burden although individuals must still adhere to injection dose schedules.16,72 LA PrEP 
has a long pharmacologic tail and will likely require oral PrEP co-administration to avoid 
subtherapeutic drug levels upon initiation and discontinuation.72 LA cabotegravir has been detected 
one year after discontinuation in 14% of users.77  
Subtherapeutic drug levels can increase the risk of HIV viral resistance if HIV is acquired 
during this time which is concerning among those with poor adherence or those with acute HIV 
37 
 
infection who were improperly initiated on PrEP.16,72,77 Mutations conferring resistance to 
nucleoside and non-nucleoside reverse transcriptase inhibitors have been appreciated in PrEP users 
in the setting of subtherapeutic drug levels.2,16 Mutations conferring significant resistance to all 
integrase inhibitors have been appreciated among macaque studies assessing viral resistance 
mutations in the setting of sub-therapeutic LA cabotegravir levels.77 Resistance to integrase 
inhibitors and nucleoside reverse transcriptase inhibitors is concerning because these are currently 
recommended as initial HIV treatment for most people in the US.78 Providers of LA PrEP may also 
need to increase clinical capacity if LA PrEP injections are to be administered in a clinical 
setting.72 Additional emerging PrEP delivery systems include injections with better tolerability, 
implants, and new classes of medications.72 
Psychosocial Benefits of PrEP 
 PrEP significantly reduces the risk of HIV acquisition, provides an opportunity to engage 
at-risk populations in STI screening, and can have psychological and emotional benefits for PrEP 
users.9,10,21,79 In qualitative studies, PrEP users and PLWH have reported feeling empowered with 
reduced fear of HIV transmission and subsequent increased feelings of intimacy and pleasure 
surrounding sex.9,79 PrEP user empowerment can be driven by control over their sexual health 
reducing the need to rely on others to use condoms, adhere to ART, or disclose their HIV status.9,79 
PrEP can also reduce HIV-related stigma as PrEP user social networks may be more inclusive of 
PLWH where serosorting, exclusion of PLWH from social networks due to HIV status, has 
occurred.9 PrEP users have reported increased inclusion of PLWH in relationships, knowledge of 
HIV, and reduced anxiety, fear, or shame related to unknown HIV status.9,63 
PrEP Uptake 
 In 2015, 1.2 million adults in the US were estimated to be eligible for PrEP of which the 
primary HIV risk factors were MSM (71.1%) and injection drug use (22.5%).80 PrEP-eligibility has 
varied by location and race with Blacks in the South in highest need.80 US PrEP uptake has 
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increased since 2013.9 However, PrEP uptake in the US has been considered slow by public health 
practitioners with disparities in racial and geographic access due to a combination of real and 
perceived provider and client barriers including awareness, cost, stigma, and medical system 
mistrust.17,81–85  
A PrEP-to-need ratio (PnR) analysis of a national US prescription database using fourth 
quarter 2017 data found variation in PrEP use with 30% of PrEP users in the South (PnR 1.0), 30% 
in the Northeast (PnR 3.3), 23% in the West (PnR 2.1), and 17% in the Midwest (PnR 2.4).15 Low 
PnR was found in states with lower rates of health insurance coverage, higher rates of poverty, and 
larger population of Black residents which highlights disparities among those most at-risk for HIV 
and those most likely to use PrEP.15 A county-level assessment of US PrEP providers relative to 
MSM PrEP-eligible populations in 2017 found PrEP-deserts (areas without PrEP providers within 
a 30-minute drive) were present among all US regions with worse disparities outside of urban 
centers and in the South (17.1% compared to 5.4% in the Northeast).83 Rural areas of the West, 
Midwest, and states of Georgia and Texas were more likely to have significant PrEP-deserts with 
no PrEP providers within a 90-minute drive.83 
Systematic barriers to PrEP uptake have included ineffective community engagement, lack 
of clinical capacity, and cost.81 Inadequate identification and referral of PrEP-eligible clients can 
limit PrEP access, legal restrictions can limit access to minors, and lack of funding or insurance 
coverage has been the most commonly cited barrier to PrEP access by patients and providers.81 
PrEP messaging has largely targeted cisgender MSM with less advertising toward injection drug 
use, transgender, heterosexual, and minority populations that face unique stigma and disparities 
accessing healthcare services.81 A cohort of 33 PrEP-eligible PWID in Massachusetts reported 
multiple barriers to PrEP. Limited awareness of PrEP was the primary individual level barrier, and 
additional barriers included drug use, homelessness, inconsistent engagement with the medical 
system, and possible incarceration.84 
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Barriers to formal PrEP access have prompted use of self-sourced PrEP through online 
purchases or other informal channels.86 Informal PrEP users may forgo recommended screenings 
(like HIV or renal function tests) and the quality and safety of informal PrEP sources is unknown.86 
A qualitative study with 20 informal PrEP using MSM in the United Kingdom in 2017 found that 
most users self-sourced PrEP through online purchase and one participant sourced PrEP from the 
ART his partner used as HIV treatment.86 Many users verbalized concern about the legitimacy of 
products purchased online but chose online purchase after seeing online PrEP advertised in a 
medical setting or after failing to obtain PrEP through formal sources because PrEP was only 
available through clinical trials in the United Kingdom at that time.86 Informal PrEP users reported 
administering both daily and event-driven PrEP, and obtained information about PrEP dosing and 
side-effects online, from medical providers and friends.86 The authors discussed that informal PrEP 
users heavily relied on social networks for information and support, and users could benefit from 
tailored interventions to promote adequate PrEP-related education, screening, and monitoring.86   
Patient and Provider Barriers to PrEP Uptake 
Patient barriers to PrEP uptake have included lack of knowledge of PrEP availability, low 
awareness of HIV risk, and concerns about cost, side-effects, adhering to a daily pill schedule, and 
stigma or mistrust of the medical system particularly among racial minorities, MSM, transgender 
women, and PWID.9,81,82 PrEP is largely covered by insurance companies although many 
individuals with and without insurance require financial assistance to obtain PrEP 
(tenofovir/emtricitabine has been estimated to cost over $10,000 per year).82,87,88 Financial 
assistance programs for copay and lab costs require knowledge of the medical system and clients 
often need assistance navigating these bureaucratic processes.82 Furthermore, individuals with 
government insurance (Medicare, Medicaid, and TRICARE) and minors under the age of 18 with 
insurance coverage through a parent (but prefer not to use insurance due to confidentiality) are not 
eligible for private pharmaceutical payment assistance programs.81 
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Persistent stigma and racism surrounding HIV, homophobia, transphobia, perceived 
promiscuity associated with PrEP use can prohibit eligible clients from accessing or using 
PrEP.81,82,85 A qualitative study comparing perceptions of homophobia and racism as barriers to 
PrEP among 35 gay, bisexual and MSM from sites in Massachusetts and Mississippi reported 
Black MSM had higher mistrust of the medical system and reported experiences of anti-gay or 
HIV-related stigma compared to non-Hispanic Whites.85 A qualitative study of 14 MSM PrEP 
users in Seattle, Washington reported fear of PrEP-related stigma and concern about being labeled 
as promiscuous or irresponsible for using PrEP by peers and medical providers.63 PrEP-related 
stigma can lead to feelings of shame, guilt, and internal conflict regarding respondents’ sexual 
health and PrEP use.63 
Provider barriers to prescribing PrEP have included concerns about inadequate knowledge 
or experience with PrEP; concerns about high cost or poor insurance reimbursement that may 
burden the patient or practice; risk of toxicity or side-effects; patient adherence and HIV resistance; 
risk compensation; prejudice and stigma toward those at-risk for HIV; and feeling that PrEP was 
not within their domain.17,81 There has been a significant paradox between ideal PrEP providers and 
those most likely to care for PrEP-eligible clients.81 HIV specialists (those most knowledgeable 
about PrEP) are less likely to see HIV negative PrEP-eligible clients while primary care providers 
(those most likely to see PrEP-eligible clients) are often less trained on providing PrEP.81  
PrEP Adherence and Seasons of Risk 
High attrition to PrEP has been appreciated.18,89,90 A review of 7,148 PrEP users from a 
national US pharmacy database from 2015 to 2017 revealed only two of five clients persisted with 
PrEP for two years.18 Fifty-six percent of the cohort continued PrEP through the first year of use, 
and 63% of those who continued PrEP through year one continued PrEP through year two.18 
Factors associated with increased adherence were male, over age 24, copay less than $20, and 
having commercial insurance.18 Women and youth age 18 to 24 were less likely to have persistent 
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PrEP use after one year.18 The Adolescent Trials Network 110/113 study compared self-adherence 
to PrEP with tracked pill bottle systems and drug concentrations via hair sample and dried blood 
spots among 243 participants age 15 to 24 years.89 By week 48, half of the adolescent participants 
took fewer than two PrEP doses per week per hair or blood measures, 20% took daily PrEP as 
directed, and adherence self-report was generally overestimated.89  
A retrospective review of 107 PrEP users at five outpatient clinics associated with an urban 
academic medical center in New York from 2011 to 2015 found that 58% of PrEP users 
discontinued PrEP within the first six months.91 The primary reason for discontinuing PrEP was a 
change in perceived HIV risk due to ending a relationship with a partner living with HIV.91 Factors 
associated with PrEP discontinuation were heterosexual orientation and initiation of PrEP due to 
having a sex partner living with HIV.91 Age, gender, race, and insurance status were not associated 
with PrEP discontinuation.91 
A longitudinal cohort qualitative survey of 36 former PrEP users who identified as gay or 
bisexual men found that primary reasons for discontinuing PrEP included cost, insurance 
discrepancy, side-effect, or difficulty taking a pill daily.90 Many participants also reported 
fluctuations in behavior resulting in lower perceived HIV risk.90 Behavior changes that lead to a 
perceived lower HIV risk included decreased number of partners, engagement in drug or alcohol 
treatment, condom use, and TasP among monogamous serodiscordant partnerships.90 Former PrEP 
users who discontinued PrEP due to perceived lower HIV risk also reported intent to restart PrEP if 
risky behaviors were resumed.90  
Periodic or cyclical fluctuation in risk behavior has been termed ‘Seasons of Risk’ and has 
impacted willingness to use PrEP among multiple eligible populations.92 A qualitative study of 38 
MSM and male sex workers assessing seasonal risk in Providence, Rhode Island in 2012 found 
increased risk and willingness to use PrEP during periods of vacation or holiday, summer social 
activities, and increased drug and alcohol use.92 The majority of male sex workers reported 
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substance use with increased perceived risky behavior during periods of drug use or relapse, 
poverty, and housing insecurity.92 Male sex workers reported increased PrEP interest but decreased 
PrEP access during periods of increased risk due to poverty, homelessness, lack of transportation, 
feelings of hopelessness or shame, and not prioritizing health.92  
An internet survey of 7,305 MSM in the US in 2013 found that sexual risk behavior was 
generally seasonal with increased risk during periods of vacation and travel.93 Daily PrEP 
administration was a reported barrier among 92.6% of survey respondents, most respondents 
preferred less than daily dosing of PrEP, and 74.3% reported willingness to use daily PrEP if they 
perceived it beneficial for short periods.93 The authors discussed that administering PrEP daily for 
short intervals during periods of increased risk (like vacations) may be more attractive to PrEP-
eligible individuals than long-term daily PrEP, and more research was needed to determine if daily, 
short-term daily, or event-driven (2-1-1) PrEP would be most beneficial to study participants.93  
Data on PrEP among women in the US is lacking, and reasons for discontinuing PrEP 
among women may differ from men.94 A qualitative study of 60 women in Kenya and South Africa 
found that 47% of survey respondents would likely stop PrEP in the future.94 Those who expected 
to discontinue PrEP reported reasons of lower perceived HIV risk including no longer being 
sexually active or perceiving their partner to be of low risk.94 Some women reported they would be 
likely to discontinue PrEP due to social pressure or stigma, in perinatal periods fearing PrEP may 
harm fetal development, or due to older age.94 Four women in the study reported intent to stop 
PrEP during periods of life stress, and six reported intent to stop PrEP if they were traveling 
because they did not want to travel with medication or perceived they would not have time to 
administer the medication while traveling.94 The authors discussed that PrEP providers should 
recognize social and cultural norms, consider providing PrEP education to women and their male 
partners, and educate women on safety and efficacy of PrEP surrounding pregnancy.94 
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Interventions to increase PrEP adherence should be tailored to meet individual adherence 
barriers.95 Individuals can have difficulty obtaining refills from pharmacies, remembering to take a 
daily pill, and have attitudes or perceptions that reduce uptake and adherence to PrEP.95 LA PrEP is 
expected to improve adherence among users who have difficulty adhering to daily pill schedules, 
and event-driven PrEP may improve adherence among eligible MSM who prefer less than daily 
dosing.16,74 PrEP delivery systems can also model HRSA Ryan White HIV/AIDS Program services 
to reduce disparities in access to care and improve ART adherence among at-risk populations as 
those at-risk for HIV generally face the same barriers to care and adherence as PLWH.96 Ryan 
White HIV/AIDS Program services use a multidisciplinary approach that often includes HIV 
specialists, social workers, and mental health professionals.96 Ryan White HIV/AIDS Program sites 
that performed a comprehensive needs assessment and integrated provision of ART with primary 
care have generally demonstrated superior outcomes.96 Likewise, PrEP providers that perform a 
comprehensive needs assessment and integrate provision of PrEP with primary care may also 
increase access and adherence.96 
Cost and Resource Allocation 
Assessing cost-benefit of HIV prevention is complex and largely dependent on local 
factors including HIV prevalence, characteristics of at-risk populations, healthcare infrastructure, 
cost, and availability of resources.6,13,14,97 HIV prevention interventions are often divided into 
categories along a prevention cascade including behavior risk reduction (condoms), biomedical 
prevention (PrEP), HIV testing, linkage to care, HIV treatment and retention in care (TasP).6 In the 
US, the cost of PrEP and HIV prevention is variable and dependent on factors including generic 
availability, insurance coverage, laboratory and provider fees, 340B drug-pricing, and eligibility for 
pharmaceutical payment assistance programs.13,87,88,98 ART medications are the largest cost item to 
PrEP delivery as payers are charged over $1,000 for a 30-day supply of tenofovir/emtricitabine in 
the US.87 ART cost is often shared by insurance payers and pharmaceutical payment assistance 
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programs.88,99 Clinical care (laboratory, testing, and provider fees) are variable depending on the 
type of test ordered and are often funded by insurance payers or state and local funding among 
uninsured populations.87,99,100  
A cost analysis of unmet need (no funding coverage or inadequate funding coverage) to 
fund PrEP medication, clinical visits, and laboratory costs in the US in 2015 found that the percent 
of individuals with health insurance coverage to fund PrEP varied by transmission category (PrEP-
eligible MSM were more likely to have private insurance than women or PWID).100 The authors 
estimated the national cost of covering PrEP for all eligible individuals in 2015 was about $208 
million per year ($119 million to cover the cost of those in need of assistance for clinical care only, 
and $89 million to cover the cost of those in need of assistance for clinical care and ART).100 The 
authors discussed that providing PrEP for all eligible people is less than the allocated funds 
available for HIV care and treatment (19.7 billion in fiscal year 2016), PrEP uptake has been 
generally slow, and not all eligible people have attempted to access PrEP.100  
In the US, condom use as HIV prevention has been estimated to cost less than $4 annually 
per person while PrEP can cost over $10,000 annually per person but is more effective than 
condoms when used as directed for HIV prevention.87,97,98 PrEP has more cost-effectiveness when 
delivery is targeted toward those at highest risk for HIV, like MSM, although allocating resources 
to PrEP may divert resources from less expensive prevention methods or HIV treatment and has 
not been supported as the most cost-effective HIV prevention intervention.13,98 Conversely, 
interventions supporting HIV treatment, adherence, and retention in care (TasP) have been largely 
supported as a cost-effective strategy to maximize health benefits among varying populations, 
including heterosexual and PWID, in the US and globally.6,14,97,98 A review of HIV program cost 
analysis in 23 countries found that increasing funds to treat HIV would reduce new HIV infections 
and HIV-related death and the degree of impact varied by resource availability.14 The analysis 
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supported targeting populations with the highest HIV incidence and optimizing ART availability 
for PLWH before increasing capacity for HIV testing and counselling.14  
Resource allocation for STI and HIV prevention in LHDs is critical for population STI 
prevention.101 LHDs are a safety-net for low income, uninsured and underinsured populations, and 
are ideal providers of PrEP as they are engaged with populations at-risk for HIV.101 Data has 
supported an inverse relationship between bacterial STI incidence and LHD STI funding with 
higher rates of gonorrhea and syphilis in periods of lower funding.101,102 Despite public need, 
federal funding for public health STI prevention has declined since 2002 and future budget 
restrictions are expected.101,102 A 2013 and 2014 survey of 148 US LHDs recruited from the 
National Association of County and City Health Officials’ (NACCHO) 2010 National Profile of 
Local Health Departments survey found that 61.5% experienced STI budget cuts in the previous 
fiscal year; about 40% reduced STI clinic hours of operation and STI screening due to budget cuts 
and 6.8% closed STI clinics due to budget cuts.101 Reduced funding for LHD STI programs can 
negatively impact populations most vulnerable to HIV and STIs.101,102 
PrEP in Local Health Departments 
US public health agencies are critical providers of HIV prevention services, and LHDs are 
in an ideal position to support PrEP delivery and leverage data.1,6,101,103 Most available literature on 
PrEP delivery has been collected in clinical trial or academic settings, and little data on PrEP 
delivery in local health departments exist. Available data on PrEP delivery in LHDs have 
predominantly assessed LHD engagement or willingness to provide PrEP services. Despite the 
critical role of LHDs in STI and HIV prevention in the US, data regarding population outcomes of 
PrEP provision by LHDs is a current gap in the literature, and no literature on STI incidence among 
LHD PrEP users or PrEP provision by LHDs in the US state of Georgia could be identified. 
A 2015 US survey of 284 LHDs on PrEP engagement found 29% of respondents were 
engaged in PrEP services through activities including linkage to PrEP care (74%), PrEP education 
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to community members (51%), or participation in state or local PrEP workgroups (32%).1 LHDs 
engaged in PrEP services were most often located in the West (47%) and served large jurisdictions 
(68%).1 LHDs engaged in PrEP services were also more likely to provide HIV testing (98%), HIV 
linkage to care (83%), or operate STI clinics (81%) than those not engaged in PrEP services.1 Only 
9% of survey respondents reported actively providing PrEP and barriers to PrEP provision at the 
LHD level included concerns about clinical capacity (61%), cost to clients (53%), and lack of 
knowledge among staff (47%).1 A 2016 survey of 56 LHDs in North Carolina regarding PrEP 
provision found that two LHDs actively provided PrEP and seven referred clients to PrEP services. 
Primary reasons for LHDs not engaging in PrEP were concerns about cost, lack of PrEP 
prescribing protocol, and belief that PrEP provision was more appropriate for non-LHD clinics.104  
The NGHD, a LHD in north Georgia, aims to optimize local population HIV and STI 
health outcomes in coordination with national and state prevention goals. The Georgia Integrated 
HIV Prevention and Care Plan for 2017-2021 goals include preventing new infections, improving 
access to care and health outcomes, and reducing HIV-related health disparities.105 To achieve 
these goals, the NGHD started providing PrEP services in July 2019 in addition to previously 
existing STI and HIV prevention and treatment services. PrEP services provide the NGHD an 
opportunity to screen, refer, and vaccinate a population that may otherwise be unengaged in care or 
forgo services. PrEP users at NGHD LHD study sites are routinely screened for HIV, STIs, and 
hepatitis C; mental health conditions like depression; substance use including tobacco, alcohol, and 
illicit drug use; and vaccination status. Treatment and referrals are provided as needed. 
PrEP Program Performance Evaluation 
The WHO has described PrEP delivery as a cascade of services where individuals at-risk of 
HIV are identified and linked to PrEP care, screened for interest and eligibility, provided PrEP, 
retained in care with optimal adherence, and discontinue PrEP as indicated.106 Routine program 
monitoring is essential to assess PrEP uptake, effectiveness, and to predict demand.106 The WHO 
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has recommended that program measures assess each step in the PrEP delivery cascade to 
determine if the program is reaching the target population with safe, effective, and sustained PrEP 
care.106 The WHO has suggested PrEP program measures include PrEP uptake, retention in PrEP 
care for more than three consecutive months, PrEP toxicity, and seroconversion (number of PrEP 
users who are diagnosed with HIV).106 The CDC has suggested PrEP program quality measures 
include presence of baseline HIV screening before initiating PrEP, interval HIV screening, PrEP 
medication adherence, seroconversion, and seroconversion with ART-resistant HIV.107 No national 
US PrEP program comparison benchmarks could be identified.  
A PrEP program evaluation in New York assessing 171 PrEP users from five clinics 
throughout the state from 2014 to 2015 found that the primary demographics of PrEP users were 
male (93.6%), white (60%), age 25-34 (46%), with predominant risk factor of anal sex (55.2%), 
and most had private insurance (66.7%).108 Twenty-four percent of the cohort discontinued PrEP 
within the 12-month study period and the majority discontinued PrEP within the first six months of 
PrEP use.108 The primary reason for PrEP discontinuation was a change in perceived HIV risk.108 
One client seroconverted with HIV between PrEP initiation and one-month follow-up, 17 PrEP 
users were found to have a bacterial STI on PrEP intake, and 9 were found to have a bacterial STI 
on 6-month screening.108 Eighty-three PrEP users responded to a survey on their experience with 
PrEP and generally reported being satisfied with PrEP with 94% of respondents reporting they 
would recommend PrEP to a friend and 82% reporting less worry of HIV.108 Thirty-three percent 
reported having insurance issues related to PrEP, and a high deductible or copay for laboratory or 
provider fees was the primary insurance-related issue.108 Staff reported that developing 
infrastructure to support PrEP delivery (PrEP-related clinical training and increased administrative 
support) was essential to successfully initiate a PrEP program.108 No program evaluation of PrEP 
services, retention in care or STI incidence among PrEP users in a Southeast US LHD setting could 
be identified despite the key role of LHDs in community STI prevention. This practice-based study 
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served to provide NGHD leadership with data to evaluate PrEP program delivery and guide 






The goal of this study was to perform an evaluation of LHD PrEP services in the North 
Georgia Health District (NGHD), a local health department that includes six counties in north 
Georgia, between July 2019 and June 2020 (the first year PrEP services were provided), quantify 
the impact of COVID-19 on NGHD STI testing services, and determine how the Thinking 
Ethically framework can be effectively applied to PrEP-related public health practice. The study 
was performed through a secondary analysis of longitudinal data obtained through a retrospective 
review of NGHD PrEP client medical records from July 1, 2019 to June 30, 2020; aggregated 
NGHD STI testing from July 1, 2017 to June 30, 2020; and an analysis of literature cited in this 
study. The study was approved by the Georgia Southern University Institutional Review Board 
(Appendix A). 
Data obtained from this study were intended to be applied by NGHD leadership to guide 
future PrEP service delivery, determine the rate of bacterial STI diagnosis among PrEP users, and 
determine what additional services were provided to PrEP users beyond STI prevention. Outcomes 
included PrEP user demographics; length of time users were enrolled in the program; diagnosis of 
HIV, gonorrhea, chlamydia, syphilis among PrEP users; type of additional services provided to 
PrEP users; sum of NGHD STI tests performed; and ethical considerations to PrEP services 
identified via literature review. It was assumed that PrEP services provide an opportunity to engage 
a population that may otherwise forgo health services and routine STI screening. Individuals with 
asymptomatic STIs may forgo routine STI screening with subsequent delays in STI diagnosis and 
treatment. Routine STI screening among PrEP users benefits timely STI treatment and prevention.  
The study period included the onset of the 2020 COVID-19 pandemic, and it was assumed 
that the COVID-19 pandemic impacted NGHD STI and PrEP service delivery. The number of total 
STI tests (HIV, gonorrhea, chlamydia, and syphilis) provided by the NGHD between July 1, 2017 
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and June 30, 2020 were assessed in attempt to quantify the impact of the COVID-19 pandemic on 
NGHD STI services. Total STI tests provided during this period provided NGHD leadership with 
baseline data to determine when STI services return to pre-pandemic quantity. NGHD STI testing 
services were assessed because HIV prevention and PrEP should be considered in the context of a 
broad STI prevention strategy.10,11 The study served to answer the following research questions:  
1. How can the Thinking Ethically framework be used to inform public health practitioners on 
PrEP-related decision-making? 
2. Did NGHD PrEP services reach those most at-risk for HIV in the district? 
3. How long did PrEP users stay in the program? 
4. What additional services were provided to PrEP users beyond STI prevention?  
5. How many asymptomatic bacterial STIs were diagnosed among PrEP users? 
6. How much did NGHD STI testing change in the period associated with the onset of the 
COVID-19 pandemic?  
The research questions were developed with consideration to NGHD STI screening 
priorities along with CDC and WHO recommended PrEP practice quality indicators which include 
appropriate screening, retention in care, and the number of patients with confirmed HIV diagnosis 
while prescribed PrEP medication.106,107 The questions were framed with regard to the Thinking 
Ethically framework which incorporates multiple ethical principles and uses a stepwise approach to 
ethical decision-making.5 All Thinking Ethically principles (justice, utility, rights, common good, 
and virtue) were analyzed in research question 1, and the principles of justice (the fair distribution 
of resources) and utility (acting to produce the greatest net benefit) were used to frame research 
questions 2 – 6.5 Ethical considerations surrounding NGHD PrEP services have included reaching 
the target population as those at-risk for HIV are often vulnerable or hard to reach and may require 
allocation of additional resources,3 and the potential impact of PrEP services on the broader STI 
landscape as PrEP use has been associated with increased bacterial STI incidence and those at-risk 
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for HIV are often at-risk for other STIs.10,11 PrEP user demographics and length of time enrolled in 
the PrEP program were assessed to determine if NGHD PrEP services equitably reach those at-risk 
for HIV in the district (justice approach). Additional non-HIV prevention services provided to 
PrEP users (like vaccination or referrals) and asymptomatic bacterial STI diagnosis among PrEP 
users were assessed to weigh the net benefits of NGHD PrEP services and potential impact of PrEP 
provision on the STI landscape (utility approach).  
It was assumed that the medical record was an accurate reflection of the medical encounter 
and the Thinking Ethically framework would benefit PrEP-related public health decision-making in 
practice. It was expected that the NGHD had between 50 and 100 PrEP users within the study 
period and minority of PrEP users were prescribed PrEP with on-demand (2-1-1) administration. It 
was expected that the NGHD PrEP user population was largely homogenous in race (White), 
ethnicity (non-Hispanic), gender (male), and primary HIV risk factor (MSM), and differed in age. 
It was estimated that length of time in PrEP care would mirror the experience of other PrEP clinics 
with 20-50% of PrEP users discontinuing PrEP within the first six months. Providing PrEP services 
was expected to benefit NGHD ability to identify asymptomatic bacterial STIs through routine 
screening. Duplicate bacterial STI diagnoses were expected in some cases and were not considered 
an error in data collection (for example, clients diagnosed with pharyngeal and urethral gonorrhea 
on the same screening encounter). It was expected that PrEP users were provided with additional 
services including routine vaccination, referrals (primary care, mental health care, social services), 
and tobacco cessation counseling as indicated. It was expected that the largest disruption in NGHD 
STI testing services associated with the onset of the COVID-19 pandemic occurred between April 
and June 2020. 
The NGHD provides PrEP to eligible clients using the Georgia Department of Public 
Health (DPH) Registered Nurse Protocol and CDC guidelines. NGHD clients are eligible for PrEP 
if they meet DPH and CDC criteria which include a primary HIV risk factor of MSM, 
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heterosexually active men and women, and PWID with additional risk factors including multiple 
partners, recent bacterial STI, inconsistent condom use, or partner living with HIV.2 Clients must 
have documented negative HIV test and no sign of acute HIV, no medical contraindication to 
tenofovir/emtricitabine, and be willing to return for follow-up one month after starting PrEP and 
three months thereafter. Screening for syphilis, gonorrhea, and chlamydia via 3-point testing 
(pharynx, urethral or vaginal, and rectal) is performed on the initial PrEP encounter and every six 
months (more frequently as needed). The NGHD postponed in-person PrEP visits in the second 
quarter of 2020 due to the COVID-19 pandemic during which time PrEP users were provided with 
prescription refills if they were able to be contacted by phone, had no symptoms of acute HIV, 
verbalized adherence to PrEP and willingness to continue therapy.  
Sample and Population 
The cohort was selected via convenience sampling. Medical records of all PrEP users in 
the NGHD from July 2019 to June 2020 (the first year that PrEP services were provided) were 
reviewed. Sixty-three clients obtained PrEP from the NGHD during the study period and were 
included in the study. During the study period, the NGHD provided PrEP only to those over 18 
years of age, so only data from those of 18 years or older were included in the study. NGHD PrEP 
users who tested positive for HIV were to be included in the cohort until date of HIV diagnosis, but 
no NGHD PrEP users were diagnosed with HIV during the study period. The study also examined 
the total number of STI tests performed by the NGHD from July 2017 through June 2020 to 
quantify the degree of service delivery change associated with the onset of the COVID-19 
pandemic. This data included all HIV, gonorrhea, chlamydia, and syphilis tests performed at 
NGHD clinic sites. Tests of HIV, gonorrhea, chlamydia, and syphilis not performed at NGHD 




Data to inform analysis of the Thinking Ethically framework used literature cited in this 
study (research question 1). Client data was obtained via a retrospective chart review of NGHD 
electronic medical record data from all NGHD PrEP clinic sites (research questions 2 – 6). Data 
obtained included PrEP user age, race/ethnicity, sex/gender, HIV risk factor, bacterial STI 
diagnosis, length of time on PrEP, and NGHD clinic site. Data on presence of STI symptoms at the 
time of bacterial STI diagnosis was obtained to determine the rate of asymptomatic STIs diagnosed 
through routine program STI screening. Data on additional services provided (like vaccination and 
referrals) were obtained to assess benefits of PrEP provision beyond STI prevention. To protect 
privacy, data was recorded in deidentified form, each NGHD clinic site was assigned a confidential 
name (Clinic A, Clinic B, Clinic C), and clinics with fewer than 10 PrEP users were reported in 
aggregate form instead of confidential clinic name to protect client confidentiality as some NGHD 
sites had low PrEP program census. 
NGHD district-level HIV, gonorrhea, chlamydia, and syphilis data from July 2017 to June 
2020 were assessed using an electronic medical record STI report utilized by the district to 
routinely assess STI incidence (research question 6). This report had no patient identifiers and was 
captured in Excel software. Data was captured using a secured on-site computer on an Excel file 
without any personal identifiers and stored on the researcher’s password-protected computer and 
NGHD internal password-protected virtual drive. 
Data Analysis 
Research Question 1 
Analysis and synthesis of the Thinking Ethically framework (research question 1) was 
performed using literature cited in this study and study outcomes of research questions 2 – 6. 
Outcomes included pairing each Thinking Ethically principle (utilitarian, justice, rights, common 
good, and virtue) with a PrEP-related ethical consideration. An analysis was performed to 
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determine how the Thinking Ethically framework benefits PrEP-related public health practice and 
decision-making. 
Research Questions 2 – 5  
Chart review data from July 1, 2019 to June 30, 2020 was analyzed using Excel and SPSS 
version 27 software to answer research questions 2-5. NGHD PrEP user demographic variables 
(clinic site, age, race/ethnicity, sex/gender, and HIV risk factor), presence of any additional 
services provided to PrEP users, months in program, and asymptomatic STI diagnosis among PrEP 
users were assessed. To determine how long NGHD PrEP users stay in the program, client length 
of time using PrEP was assessed in months (four weeks) from the initial encounter date to the end 
of the study period or to the date of last documented contact with the client, whichever came first. 
Discontinuation dates that fell between two months were rounded to the nearest month, and data of 
one client who discontinued and restarted PrEP within the study period reflected the sum months of 
program participation.  
Descriptive statistics including means, standard deviation, and frequencies were used to 
answer research questions 2 – 5. Negative binomial and multiple logistic regression models were 
performed to further assess research question 3. Regression analyses included 62 of the 63 PrEP 
users in the study. Cohort demographic variables with low events per variable were transgender 
(n=1), IV drug user HIV risk (n=1), and clients prescribed on-demand (2-1-1) PrEP (n=1). The one 
transgender female was coded as female, the one IV drug user was excluded, and the one on-
demand PrEP user was coded in the same way as daily PrEP users to reduce the risk of type 1 error 
due to overfit of cohort data (Table 3.1). A forced entry approach including all independent 
variables on the first step was used because previous literature suggested factors of age, HIV risk, 
and race/ethnicity have been associated with PrEP use.18,85,89,91   
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Table 3. 1. Regression modeling variables and type 
Study Variable Type 
Dependent variables Months in Program Continuous 





     Clinic A 
     Clinic B 
     Clinics C/D/E 
Categorical 
 Sex/Gender: 
     Male 
     Female 
Categorical 
 Race/Ethnicity: 
     Black non-Hispanic 
     White Hispanic 
     White non-Hispanic 
Categorical 
 Age Continuous 
 Primary HIV Risk Factor: 
     MSM 
     Heterosexual risk 
Categorical 
 
Negative binomial regression. Negative binomial was performed to assess for association 
between PrEP user demographics factors on probability of number of months in the PrEP program 
(research question 3). The negative binomial regression model is a linear Poisson distribution with 
the addition of a 𝜆 parameter to consider data variance in the equation. This improves the model fit 
for data that is over-dispersed (variance greater than the mean) compared to a Poisson distribution 
that assumes variance equals the mean. The negative binomial 𝜆 parameter follows a gamma 
distribution (a continuous probability function that assesses the variance and mean to determine the 
average waiting time for skewed events with a natural minimum of 0). Test assumptions were 
presence of a continuous dependent variable, observations that are independent of each other, and 
independent variables that have a multiplicative effect on the event. The following regression 
function was used to predict the probability of months in program: 













; 𝑛 ≥ 0 
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where 𝑃(𝑦𝑖 = 𝑛|𝑥𝑖) is the probability of the dependent variable occurrence, 𝛤 is the gamma 
distribution, 𝑦𝑖 is the dependent variable, 𝑛|𝑥𝑖 is the independent variable with a positive 
continuous 𝑛, 𝜆𝑖 is an exponential equation:  
exp(𝑥𝑖𝛽) 
where 𝑥𝑖 is the independent variable and 𝛽 is the beta coefficient (a standardized measure 
indicating the degree change in the outcome variable for every 1-unit change in the independent 
variable), and 𝑚𝑖 is an exponential equation:  
exp[(2 − 𝑃)𝑥𝑖𝛽 − ln(𝛿)] 
where 𝑃 is a probability, and ln(𝛿) is the natural log of delta (a difference in measures). 
 The dependent variable was PrEP user months in program as a continuous numerical 
measure. The independent variables were PrEP user demographic factors. Clinic site compared 
enrollment at Clinic A or Clinic B to Clinics C/D/E. Sex/gender compared females to males. HIV 
risk factor compared those of heterosexual risk to MSM. Race/ethnicity compared Black non-
Hispanic or White Hispanic PrEP users to White non-Hispanic PrEP users. Age in years at program 
enrollment was a covariate. Independent variables were considered statistically significant if the 
corresponding p-value was less than 0.05. 
Multiple logistic regression. Multiple logistic regression was performed to assess for 
association between PrEP user demographic factors on odds of retention in care of four or more 
months (research question 3). Four or more months was selected in accordance with recommended 
WHO program measures to assess retention in care by consecutive PrEP use greater than three 
months.106 The multiple logistic regression model solves for the odds of an outcome occurring and 
calculates the natural log of the odds ratio so that the relationship can be plotted linearly. Test 
assumptions were presence of a binary dependent variable, observations that are independent of 
each other, little to no multicollinearity among independent variables, and independent variables 
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should have 10 or more events per variable. The following regression function was used to predict 








) is the expected log of the odds that the outcome is present, ?̂? is the expected 
probability the outcome is present, 𝑋1 through 𝑋𝑝 are independent variables, and 𝑏0 through 𝑏𝑝 are 
regression coefficients of the line. 
The dependent variable was PrEP user months in program coded as ‘yes’ if the PrEP user 
months in the program were four or more and ‘no’ if PrEP user months were three or less. The 
independent variables were PrEP user demographic factors. Clinic site compared enrollment at 
Clinic A or Clinic B to Clinics C/D/E. Sex/gender compared females to males. HIV risk factor 
compared those of heterosexual risk to MSM. Race/ethnicity compared Black non-Hispanic or 
White Hispanic PrEP users to White non-Hispanic PrEP users. Age in years at program enrollment 
was a covariate. Independent variables were considered statistically significant if the corresponding 
p-value was less than 0.05. 
Research Question 6 
The total number of STI tests performed by the NGHD was calculated from July 2017 
through June 2020 using Excel software to determine how much NGHD STI testing changed in the 
period associated with the onset of the COVID-19 pandemic (research question 6). STI testing 
totals from July 2018 through June 2020 were assessed quarterly and totals were compared using 
descriptive statistics. STI testing totals from July 2017 to June 2018 were excluded due to missing 
or inconsistent data and it was determined that two years of historic STI testing data (July 2018 to 






Thinking Ethically About PrEP 
Question 1: How can the Thinking Ethically framework be used to inform public health 
practitioners on PrEP-related decision-making? 
Providers of PrEP, HIV and STI care must make complex ethical decisions on resource 
distribution and clinical services that can have significant public health impact. The Thinking 
Ethically framework is of practical use to inform public health practitioners on PrEP, HIV and STI-
related decision-making by leading the practitioner to think critically and consider multiple ethical 
perspectives in a step-by-step manner. Use of multiple ethical perspectives is necessary to 
adequately assess the multifaceted nature of PrEP as decision-makers must consider available data, 
available resources, and possibly conflicting stakeholder perspectives when providing PrEP 
services.3 The Thinking Ethically framework facilitates practitioners to select the best plan of 
action by first collecting data on an ethical issue and then evaluating outcomes against each ethical 
principle (utilitarian, rights, justice, common good, and virtue).5 The following section serves to 
demonstrate how the Thinking Ethically framework can be used to inform public health 
practitioners on PrEP-related decision-making. Each question posed in the Thinking Ethically 
framework will be addressed to exemplify the stepwise decision-making process as it applies to 
providing PrEP care at the Local Health Department (LHD) level. 
Which option will produce the most good and do the least harm? (The utilitarian 
approach)5 The best decision from the utilitarian approach is one that produces the most good and 
least harm for those impacted by the decision (greatest net gains).5 LHDs are key providers of HIV 
and STI prevention, clinical, and data management services in the community101,103 and are 
therefore ideal providers of PrEP services. Areas of high HIV incidence (like the Southeast US) 
can have the greatest benefit from PrEP provision.23 PrEP services benefit timely bacterial STI 
diagnosis and treatment10 and serve as an opportunity to engage a population that may otherwise 
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forgo medical care. In this study, 75% of the bacterial STIs identified among NGHD PrEP user 
were asymptomatic. Providing PrEP care offered an opportunity to identify, treat, and prevent 
further transmission of asymptomatic STIs as it was assumed that those with asymptomatic STIs 
may have delayed STI screening if they had not been engaged in PrEP services. About half of 
NGHD PrEP users were also provided with non-HIV-related services including vaccination, 
tobacco cessation counseling, and referrals as indicated; it was assumed that PrEP users may not 
have engaged the medical system to obtain these services in absence of PrEP care. PrEP users have 
also reported psychosocial benefits of PrEP including feelings of empowerment and reduced fear of 
HIV.9 
Potential risks of PrEP have included adverse reactions from ART and HIV viral resistance 
among PrEP users if seroconversion occurs in the setting of subtherapeutic drug levels.2 ART used 
in oral PrEP has been generally well tolerated, and the risk of developing HIV viral resistance 
among oral PrEP users has been low.2 The rate of HIV viral resistance among Long Acting PrEP 
(LA PrEP) users in the community is not yet known as LA PrEP is being studied in ongoing 
clinical trials at the time of this study, although data has supported a risk of HIV viral resistance 
among macaque LA PrEP models that can have significant implications for HIV care.77 LHD PrEP 
providers will need to determine if the risk of HIV resistance outweighs the right of PrEP users to 
access LA PrEP once approved and available for use. 
Which option best respects the rights of all who have a stake? (The rights approach)5 The 
best decision from the rights approach is one that honors the moral rights of those affected.5 Moral 
rights include dignity, autonomy, privacy, to be told the truth and not injured.5 Ethical rights 
surrounding PrEP can include the right to access PrEP, right to safe and effective therapy, and right 
to privacy. LHD provision of PrEP services can serve to improve an individual’s right to access 
PrEP as LHDs often provide care to vulnerable populations at-risk for HIV.101 Oral PrEP has been 
generally well tolerated and considered up to 99% effective as HIV prevention when used as 
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directed.2 Long Acting PrEP (LA PrEP) has also demonstrated high effectiveness in HIV 
prevention in clinical trials although the risk of LA PrEP on HIV viral resistance in the community 
is not yet known.72 The right to privacy surrounding PrEP can be complex; regulation requiring 
involvement of parents in PrEP care may be required for minors.81 PrEP users may also be subject 
to disclosures from laboratories or health insurers. For example, the primary insurance holder (like 
a parent, guardian, or spouse) may receive an itemized statement of service charges or payments 
from the laboratory or insurer that could inadvertently disclose PrEP use among minors or adult 
PrEP users who are not the primary insurance holder.  
Which option treats people equally or proportionately? (The justice approach)5 The best 
decision from the justice approach is one that treats everyone equally, or unequally with a 
justifiable standard (for example, income that is stratified by skill).5 When providing PrEP, LHDs 
must determine how to fairly appropriate resources to provide PrEP to multiple at-risk populations 
in addition to other public health priorities, like the ongoing COVID-19 pandemic response. PrEP-
deserts have been appreciated in rural areas with worse access in rural areas of the US South,83 and 
a low PrEP-to-Need (PnR) ratio has been appreciated in states in the South and non-Medicaid 
expansion states compared to other regions of the US.15 This indicates that PrEP is not currently 
equally distributed among those at-risk in the US. LHDs often serve as a healthcare safety net and 
LHDs in Southeast and rural areas could improve PrEP distribution inequality by providing PrEP 
services.  
The NDHD integrated PrEP with its preexisting STI screening and treatment program in 
2019, and staff was allocated to perform administrative tasks associated with PrEP care (like 
assisting clients with enrollment in pharmaceutical payment assistance programs). The majority of 
NGHD PrEP users were MSM despite a known population of PWID30 indicating that the NGHD 
did not successfully reach all groups at-risk for HIV in the service area. Additional resources would 
need to be allocated to reach and retain the NGHD IV drug user population in PrEP care as PWID 
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have reported additional barriers to PrEP uptake including poor awareness, drug use, and low 
socioeconomic status.84  
Which option best serves the community as a whole, not just some members? (The common 
good Approach)5 The best decision from the common good approach is one that benefits 
community welfare for everyone (including vulnerable populations).5 Services including public 
education, police and fire response are often evaluated from the common good approach.5 Ethical 
considerations to LHD PrEP assessed in the utilitarian approach are also generally applicable for 
analysis under the common good approach. Providing PrEP services can reduce HIV transmission 
risk,2 improve timely diagnosis and treatment of non-HIV STIs,10 and provide an opportunity to 
vaccinate individuals who may have otherwise forgone services. These services are beneficial to 
the community as reducing HIV and STI transmission among individuals reduces community level 
incidence, and vaccinating individuals improves community-level immunity. There has been 
debate on whether to allocate ART to PrEP or HIV treatment in resource limited settings where 
access to ART for treatment may be impacted if resources were allocated to PrEP care.3 Literature 
has supported prioritizing ART for HIV treatment (Treatment as Prevention) instead of PrEP in 
resource limited settings.98 The NGHD had adequate resources to initiate PrEP services without 
restricting HIV treatment services. 
Which option leads me to act as the sort of person I want to be? (The virtue approach)5 
The best decision from the virtue approach is one that enable decision-makers to act in accordance 
with their highest character standard.5 Honesty, compassion, integrity, self-control, and prudence 
are common virtues used to evaluate acting from one’s best self.5 PrEP-related virtues include 
compassion, fairness, and overcoming stigma and discrimination that surrounds HIV, STI, and 
PrEP services. PrEP users have reported reduced stigma, fear and discrimination against PLWH 
because of PrEP.9 Conversely, PrEP-eligible individuals have reported a fear of being labeled 
promiscuous or irresponsible as a barrier to PrEP use.63 Many at-risk groups (MSM, transgender 
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individuals, minorities, PWID) have also reported fear of stigma or discrimination when engaging 
the medical system.84,85 LHDs should work to provide outreach and PrEP care in a culturally 
sensitive manner to overcome stigma-related barriers to PrEP, HIV and STI prevention. 
North Georgia Health District PrEP Services 
Question 2: Did NGHD PrEP services reach those most at-risk for HIV in the district? 
There were 63 NGHD PrEP users in the study period. NGHD Clinic A served 35 clients, 
Clinic B served 18 clients; Clinics C, D, and E (C/D/E) served a total of 10 clients. Most NGHD 
PrEP users identified as male followed by female and transgender. Most PrEP users identified as 
White non-Hispanic followed by Black non-Hispanic and White Hispanic. The primary HIV risk 
factor among PrEP users was MSM followed by heterosexual contact and intravenous drug use. 
PrEP users were widely distributed in age with a range of 18 to 69 years (Figure 4.1). Most PrEP 
users were under age 35 with 39.7% between 18 to 24 years followed by 25 to 34 years, 35 to 44 
years, and over 45 years (Table 4.1). The median age was 28 years and mean age was 30 years with 
a standard deviation of 11.5.  




































Table 4. 1. Count of cohort demographic factors 
Demographic factor n (%) 
Clinic Site: 
     Clinic A 
     Clinic B 










     Male 
     Female 










     Black non-Hispanic 
     White Hispanic 









Age in years 
     18-24 
     25 to 34 
     35 to 44 











Primary HIV Risk Factor: 
     MSM 
     Heterosexual risk 










Study sites were found to have differing client demographic factors (Table 4.2). PrEP users 
at Clinic A were 62.9% male followed by female, 48.6% White non-Hispanic followed by Black 
non-Hispanic and White Hispanic, and with primary HIV risk factor of heterosexual risk followed 
by MSM and injection drug use. PrEP users at Clinic B were 88.9% male followed by female and 
transgender, 72.2% White non-Hispanic followed by Black non-Hispanic and White Hispanic, and 
with primary HIV risk factor of MSM followed by heterosexual risk. PrEP users at Clinics C/D/E 
were 90% male followed by female, 80% White non-Hispanic followed by White Hispanic, and 




Table 4. 2. PrEP user demographics by clinic site 
Demographic Factor Clinic A Clinic B Clinics C/D/E 
Sex/Gender:           
Male 62.90% n=22 88.90% n=16 90% n=9 
Female 37.10% n=13 5.60% n=1 10% n=1 
Transgender Female 0% n=0 5.60% n=1 0% n=0 
Race/Ethnicity:           
Black non-Hispanic 40% n=14 11.10% n=2 0% n=0 
White non-Hispanic 48.60% n=17 72.20% n=13 80% n=8 
White Hispanic 11.40% n=4 16.60% n=3 0% n=2 
Primary HIV Risk Factor:           
MSM 42.90% n=15 83.30% n=15 90% n=9 
Heterosexual 54.30% n=19 16.70% n=3 10% n=1 
PWID 2.90% n=1 0% n=0 0% n=0 
 
Question 3: How long did PrEP users stay in the program? 
The NGHD had 22 active PrEP clients at the end of the study period and 41 of 63 clients 
(65%) discontinued PrEP use during the study period. Of the 41 clients that discontinued PrEP, 
90.2% (n=37) were lost to follow-up with unknown or undocumented reason in the medical record, 
4.9% (n=2) discontinued due to a change in HIV risk, 2.4% (n=1) moved out of the service area, 
and 2.4% (n=1) discontinued due to medication side effect. The highest monthly NGHD PrEP 
census was in January 2020 (n=36), and a drop in census associated with the time of the onset of 
the COVID-19 pandemic was appreciated. NGHD PrEP census declined by 27.8% between 
January and March 2020 (36 to 26 PrEP users) but remained largely consistent between April and 
June 2020 with 23 PrEP users in April and 22 PrEP users in June (Figure 4.2).  
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Figure 4. 2. Total NGHD PrEP users per month 
 
 
Study sites were also found to have differing census, mean, median, and mode monthly 
retention during the study period (Table 4.3; Figure 4.3). Clinic A had 35 PrEP users with the 
lowest mean monthly retention (1.8 months). Clinic B had 18 PrEP users with a mean monthly 
retention of 6.9 months. Clinics C/D/E had 10 PrEP users with a mean monthly retention of 7.7 
months. Clients with less than one month enrolled in the program were found to have attended an 
intake PrEP appointment for a PrEP eligibility screen and pre-prescription laboratory testing but 
either fell out of care before being prescribed PrEP therapy or did not attend the one-month follow-
up appointment. 
Table 4. 3. PrEP user months in program by clinic site 
Clinic Site Mean Median Mode Range 
     Clinic A 1.8 1 0 0 to 11 
     Clinic B 6.9 6 6 1 to 12 
     Clinics C/D/E 7.7 11 11 0 to 12 























Figure 4. 3. PrEP user months in program by clinic site 
 
 
A negative binomial regression was performed to assess the effect of PrEP user 
demographic variables on months enrolled in the PrEP program (Table 4.4). Test assumptions of 
presence of a continuous dependent variable, observations that are independent of each other, and 
independent variables that have a multiplicative effect on the event were met. The negative 
binomial regression model was statistically significant with Omnibus test of model coefficients 
𝑋2=24.606, p=.001 with a p-value <.05 indicating significance. Clinic A was the only PrEP user 
demographic factor that was significantly associated with months in program. PrEP user months in 


























Clinic A Clinic B Clinics C/D/E
 
 
Table 4. 4. Negative binomial regression for PrEP user demographic factors on probability of months in the PrEP program 
   95% Wald CI     95% CI for EXP(B) 
Demographic Factor B Std.Error Lower Upper Wald df Sig. Exp(B) Lower Upper 
(Intercept) 2.151 .6651 .847 3.455 10.458 1 .001 8.593 2.333 31.647 
Clinic Site           
     Clinic A -1.426 .5031 -2.412 -.440 8.029 1 .005 .240 .090 .644 
     Clinic B -.120 .4328 -.969 .728 .078 1 .781 .886 .380 2.070 
     Clinics C/D/E 0a . . . . . . 1 . . 
Sex/Gender           
     Female .482 .5725 -.640 1.604 .709 1 .400 1.619 .527 4.974 
     Male 0a . . . . . . 1 . . 
Race/Ethnicity           
     Black non-Hispanic .517 .3959 -.259 1.293 1.703 1 .192 1.677 .772 3.643 
     White Hispanic -.036 .4332 -.885 .813 .007 1 .933 .964 .413 2.254 
      White non-Hispanic 0a . . . . . . 1 . . 
 HIV Risk Factor           
      Heterosexual -.822 .5545 -1.909 .265 2.196 1 .138 .440 .148 1.304 
      MSM 0a . . . . . . 1 . . 
Age in Years -.003 .0152 -.033 .027 .031 1 .861 .997 .968 1.028 
Abbreviations: CI, confidence interval 
Note: 𝑋2=24.606, p=.001 (Omnibus)  
a. Category reference variable 











A multiple logistic regression was performed to assess the effect of PrEP user demographic 
factors on odds of retention in care of four or more months (Table 4.5). Test assumptions of a 
binary dependent variable, observations that are independent of each other, and little to no 
multicollinearity among independent variables were met. Test assumption that independent 
variables should have 10 or more events per variable were met for all independent variables except 
HIV risk factor of White Hispanic (n=9). The logistic regression model was statistically significant 
with Omnibus test of model coefficients 𝑋2=36.296, p=.000 with a p-value <.05 indicating 
significance. Hosmer and Lemeshow test 𝑋2=4.183, p=.840 with a p-value >.05 indicating good 
model fit. The model explained 59.3% (Nagelkerkle 𝑅2) of the variance in months in program of 
four or more months and correctly classified 83.9% of cases compared to 54.8% of cases in the null 
model. Clinic A was the only PrEP user demographic factor that was significantly associated with 
retention in care of 4 or more months. PrEP users in Clinic A were .017 times less likely to stay in 
the program 4 or more months than those in Clinics C/D/E with a 95%CI of .001 to .218 times. 
Table 4. 5. Logistic regression for PrEP user demographic factors on odds of months in program of 
four or more months 
       95% CI for EXP(B) 
Demographic Factor B S.E. Wald df Sig. Exp(B) Lower Upper 
Clinic Site         
     Clinics C/D/E   15.500 2 .000    
     Clinic A -4.079 1.304 9.791 1 .002 .017 .001 .218 
     Clinic B .057 1.078 .003 1 .958 1.058 .128 8.755 
Age in Years -.041 .034 1.464 1 .226 .960 .898 1.026 
Sex/Gender         
     Female 1.262 1.622 .605 1 .437 3.533 .147 84.933 
HIV Risk Factor         
     Heterosexual -2.062 1.615 1.630 1 .202 .127 .005 3.014 
Race/Ethnicity         
     White non-Hispanic   3.123 2 .210    
     Black non-Hispanic 1.416 1.024 1.911 1 .167 4.120 .554 30.667 
     White Hispanic -1.071 1.144 .876 1 .349 .343 .036 3.228 
Constant 3.339 1.731 3.722 1 .054 28.204   
Abbreviations: CI, confidence interval 
Note: 𝑋2=36.296, p=.000 (Omnibus); 𝑋2=4.183, p=.840 (Hosmer & Lemeshow); .593 (Nagelkerkle 𝑅2)  




Question 4: What additional services were provided to PrEP users beyond STI prevention? 
About half (50.8%, n=32) of NGHD PrEP users had documentation of additional services 
beyond STI prevention provided during the PrEP encounter. Of the additional services provided, 17 
PrEP users were provided vaccines, 11 PrEP users were provided referrals, 5 PrEP users were 
provided alcohol reduction counseling, and 4 PrEP users were provided smoking cessation 
counseling. Vaccines provided were hepatitis A, hepatitis B, influenza, tetanus-diphtheria-
pertussis, and human papillomavirus. Referrals provided were primarily to Federally Qualified 
Health Centers for primary care, social services for food or housing assistance, mental health 
providers, or other NGHD site for vaccination (Table 4.6).    
Table 4. 6. Count of additional services provided 
Service Provided n (%) 
Vaccines   
     Hepatitis A 
     Hepatitis B 
     Influenza 
     Tdap 











Referrals   
     Primary care 
     Food or housing assistance 
     Mental health 









Health Behavior Counseling   
     Alcohol reduction counseling 






Question 5: How many asymptomatic bacterial STIs were diagnosed among PrEP users? 
Most PrEP users (81%, n=51) were not diagnosed with an STI (HIV, gonorrhea, 
chlamydia, or syphilis) during the study period, and 19% (n=12) of PrEP users were diagnosed 
with an STI during the study period. There were 16 STI cases of which 50% (n=8) were chlamydia, 
31.3% (n=5) were gonorrhea, 18.8% (n=3) were syphilis, and none were HIV. The majority of STI 
cases (75%, n=12) had no symptoms documented at time of STI screening as 62.5% (n=5) of 
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chlamydia cases were asymptomatic, 80% (n=4) of gonorrhea cases were asymptomatic, and 100% 
(n=3) of syphilis cases were asymptomatic (Figure 4.4). Sites of chlamydia diagnosis were 
pharyngeal, rectal, urethral, and vaginal, and four cases involved multiple sites. Sites of gonorrhea 
diagnosis were pharyngeal, rectal, and vaginal, and two cases involved multiple sites (Table 4.7). 
STI cases were primarily diagnosed on the PrEP intake encounter (62.5%, n=10), followed by as-
needed screening (25%, n=4) and the 6-month encounter (12.5%, n=2).  
Figure 4. 4. Presence of STI symptom at time of STI diagnosis 
 
 
Table 4. 7. Count of chlamydia and gonorrhea diagnosis site and presence of symptom  
 Total Symptomatic Asymptomatic 
Site of Diagnosis n (%) n (%) n (%) 
Chlamydia       
     Pharyngeal 
     Rectal 
     Urethral 

























Gonorrhea       
     Pharyngeal 
     Rectal 































STI Services in the time of COVID-19 
Question 6: How much did NGHD STI testing change in the period associated with the onset of the 
COVID-19 pandemic? 
STI tests performed by the NGHD declined between the first and second calendar year 
quarter (Q1 and Q2) of 2020 as well as between Q2 of 2019 and Q2 of 2020 (Figure 4.5). Between 
2020 Q1 and Q2, tests performed for HIV declined by 38% (901 to 561), gonorrhea by 51% (1,595 
to 775), chlamydia by 55% (1,588 to 707), and syphilis by 48% (482 to 250). Between 2019 Q2 
and 2020 Q2, tests performed for HIV declined by 48% (1,082 to 561), gonorrhea by 64% (2,183 
to 775), chlamydia by 68% (2,181 to 707), and syphilis by 55% (551 to 250). 





2018 Q3 2018 Q4 2019 Q1 2019 Q2 2019 Q3 2019 Q4 2020 Q1 2020 Q2
HIV 679 941 1092 1082 1031 906 901 561
Gonorrhea 1630 1643 2077 2183 1960 1626 1595 775
Chlamydia 1617 1643 2075 2181 1942 1615 1588 707











Thinking Ethically About PrEP 
Question 1: How can the Thinking Ethically framework be used to inform public health 
practitioners on PrEP-related decision-making? 
The Thinking Ethically framework was designed as an applied model to aid decision-
makers in choosing the best action through multiple ethical approaches. The Thinking Ethically 
framework was assessed to determine how it can be used to inform public health practitioners on 
PrEP-related decision-making and serve as a useful tool for LHDs deliberating whether to provide 
PrEP services. In this study, the Thinking Ethically framework was found to be feasible and 
appropriate to evaluate LHD services and provision of PrEP care. Framework theoretical concepts 
were presented in a concrete step-by-step process that translated well to public health practice and 
the use of multiple ethical approaches (utilitarian, rights, justice, common good, and virtue) was 
appropriate to assess the multifactorial impact of PrEP services. The Thinking Ethically framework 
can be applied to future PrEP considerations like how to best allocate LHD resources to provide 
PrEP services to those most at-risk or whether to provide Long Acting (LA) PrEP once available 
given the risks and resource-intensity of LA PrEP compared to currently available oral PrEP 
services. 
LHD PrEP services were considered to provide a greater net benefit than risks to 
stakeholders (utilitarian approach) through the opportunity to prevent HIV, STIs and provide non-
HIV services. Services were considered to abide by the rights of most users (rights approach) 
although dilemmas remain surrounding privacy and access to PrEP care among minors. Resources 
allocated for PrEP (justice approach) facilitated reaching at-risk populations of MSM but did not 
adequately reach PWID within the service area. PrEP services were considered to benefit all 
members of the community (common good approach) through additional non-HIV services, like 
STI prevention and vaccinations. Services were also considered virtuous (virtue approach) by 
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targeting vulnerable populations at-risk for HIV although dilemmas remain surrounding stigma of 
HIV and STIs in the community.  
North Georgia Health District PrEP Services 
Question 2: Did NGHD PrEP services reach those most at-risk for HIV in the district? 
The NGHD served 63 PrEP users between July 2019 and June 2020 which could be 
considered modest enrollment compared to other NGHD programs or PrEP programs in larger 
urban centers. The lower NGHD PrEP census was anticipated given the study period assessed the 
first year of NGHD PrEP services and the suburban and rural geographic distribution of the NGHD 
(which extends from the north Atlanta suburbs into the north Georgia mountains). Suburban and 
rural areas can face additional challenges to PrEP awareness and stigma compared to urban centers. 
NGHD PrEP services primarily reached the MSM population and PWID were considered to be 
largely underrepresented considering two counties in the NGHD service area were previously 
identified by the CDC as high-risk for HIV and hepatitis C transmission due to injection drug 
use.29,30 Additional resources would be needed for the NGHD to reach and retain PWID in PrEP 
care as drug users have faced multiple barriers to care and have been considered a hard-to-reach 
population. The predominance of youth in the cohort was consistent with populations identified as 
at-risk as youth are generally at higher risk for STIs, and the racial/ethnic distribution of PrEP users 
was consistent with the larger population demographics of the service area. 
Question 3: How long did PrEP users stay in the program? 
Low retention in PrEP care has been documented in the literature and multiple community-
based studies have reported about half of PrEP users discontinued within the first year.18,91 Program 
discontinuation may indicate an individual’s reduced risk of HIV or the existence of barriers to 
care. Low PrEP program retention supports the need to reduce barriers to PrEP care and continue 
other HIV prevention strategies like behavioral change interventions and Treatment as Prevention 
(TasP). In this study, 65% of NGHD PrEP users discontinued PrEP within the one-year study 
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period and retention in care was found to vary by clinic site. No other demographic factors were 
significantly associated with retention in care via negative binomial or logistic regression 
modeling. Clinic A had a higher census but lower retention while the other clinic sites had lower 
census but higher retention. The discrepancy in retention by clinic site is significant to program 
management as variations between clinic sites indicate a need for further exploration for internal 
consistency and quality control. Site retention discrepancies could be due to variation in site PrEP 
user demographics as Clinic A served more females and those of heterosexual HIV risk compared 
to other sites (populations that have been associated with lower retention in PrEP care compared to 
MSM).18,85 Discrepancies in clinic site retention could also be due to variation in clinic processes 
(program enrollment or follow-up), staff bedside manner, or diversion of resources toward the 
COVID-19 pandemic during the study period. 
Short retention in PrEP care poses ethical considerations to LHD PrEP program 
management including staffing resource distribution and the risk of future LA PrEP provision. 
LHDs should consider PrEP retention when distributing staffing resources between multiple 
programs as LHDs in suburban and rural areas may not have the PrEP census to justify multiple 
dedicated PrEP staff. Conversely, dedicating case-management staff to assist PrEP users facing 
psychosocial or administrative barriers to care may benefit program retention. LHDs should also 
consider retention in care when deciding whether or not to provide LA PrEP in the future due to the 
risk of HIV viral resistance if PrEP is abruptly discontinued and HIV is acquired during the period 
of LA PrEP subtherapeutic drug tail.16,77 
Question 4: What additional services were provided to PrEP users beyond STI prevention? 
Services provided beyond STI prevention were provided to 50.8% of NGHD PrEP users. 
Vaccines were the primary additional service provided (45.9%) followed by referrals (29.7%), and 
alcohol (13.5%) and smoking cessation counseling (10.8%). LHD provision of PrEP services is 
considered an opportunity to engage individuals in holistic preventative care as PrEP users may 
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forgo routine services in absence of PrEP use. Referrals provided were primarily to local low-cost 
primary care followed by mental health and social services. Referral follow-up was not assessed in 
this study and it is unknown how many clients used referral services. The presence of additional 
provided services supports that NGHD PrEP users were screened for psychosocial and medical 
needs outside of sexual healthcare and attempt to refer individuals to community resources was 
made as needed. Providing preventative services to populations at-risk for HIV can benefit both 
individual and community wellness. 
Question 5: How many asymptomatic bacterial STIs were diagnosed among PrEP users? 
Routine NGHD PrEP care includes bacterial STI screening for gonorrhea, chlamydia, and 
syphilis to detect asymptomatic STI infection. Previous literature has demonstrated bacterial STI 
infection in pharyngeal and rectal sites were more often asymptomatic compared to urethral sites 
among MSM populations.23 In this study, 19% of PrEP users were diagnosed with a bacterial STI 
during the study period and 75% of bacterial STIs diagnosed were asymptomatic. Chlamydia and 
gonorrhea were primarily diagnosed in extra-urethral sites (pharyngeal and rectal), and the majority 
(62.5%) of STI cases were diagnosed on the initial PrEP encounter. The rate of asymptomatic STI 
diagnosis in this study is higher than previous literature. In a study of 280 PrEP users in New York, 
10% of diagnosed STIs were asymptomatic and 11% were diagnosed on the initial PrEP 
encounter.59 Results of this study highlight the importance of routine global STI screening of all 
exposure sites among PrEP users in the LHD setting. 
STI Services in the time of COVID-19 
Question 6: How much did NGHD STI testing change in the period associated with the onset of the 
COVID-19 pandemic? 
 The onset of the COVID-19 pandemic impacted NGHD clinical services during the study 
period and was therefore considered in the interpretation of study results, but this practice-based 
study was not designed or intended to investigate the impact of COVID-19 on LHD PrEP and STI 
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care. To encourage social distancing during the pandemic, NGHD LHD sites ceased nonessential 
in-person encounters for all programs in the second quarter of 2020. Multiple NGHD clinical sites 
providing PrEP care diverted staffing resources toward the pandemic response including COVID-
19 testing, syndromic surveillance, contact tracing, and vaccination campaigns. Local health 
departments, like the NGHD, were (and continue to be at the time of this writing) on the forefront 
of the COVID-19 pandemic response. 
 The total number of STI tests performed by the NGHD from June 2018 to July 2020 was 
evaluated to quantify the change in STI services associated with the COVID-19 pandemic and 
provide a baseline for leadership to determine when services rebound to pre-pandemic quantity. 
Between the first and second calendar year quarter (Q1 and Q2) of 2020, testing for HIV declined 
by 38%, gonorrhea by 51%, chlamydia by 55%, and syphilis by 48%. Between 2019 Q2 and 2020 
Q2, testing for HIV declined by 48%, gonorrhea by 64%, chlamydia by 68%, and syphilis by 55%. 
Gonorrhea and chlamydia testing were correlated as they are generally tested together. The full 
impact of COVID-19 on the STI landscape is not yet known, although any reduction in STI 
incidence appreciated during the time of the pandemic could be due to a true reduction in STI 
incidence due to community social distancing or reduced screening and testing. NGHD STI testing 
services also serve as an opportunity to screen individuals for PrEP eligibility, and a reduction in 
NGHD STI services is assumed to have impacted enrollment in the PrEP program. 
 During the period of COVID-19 related clinical service disruption, NGHD PrEP 
providers refilled tenofovir/emtricitabine prescriptions if the PrEP user could be contacted by 
phone for a verbal adherence and HIV symptom screen. Many NGHD PrEP users also obtained 
prescription refills from a mail-order pharmacy in the Ryan White AIDS Drug Assistance Program 
(ADAP) pharmacy network. It is reasonable to suspect that PrEP users with reliable phone service 
were better able to be retained in care during this time and use of a mail order pharmacy likely 
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benefited PrEP users during periods of social distancing, but more research is needed to investigate 
retention trends during the COVID-19 pandemic. 
Future Research 
The COVID-19 pandemic was a significant confounding variable during the study period, 
and additional research on the impact of the COVID-19 pandemic on the STI landscape and PrEP 
care is needed as the long-term impact of the COVID-19 pandemic on STI trends, LHD fiscal 
resources, and resource distribution is not yet known. Follow-up NGHD PrEP program reviews 
should also be performed as one year is not enough time to determine long-term trends or impact of 
LHD PrEP services. Follow-up program reviews would also benefit from a state-wide evaluation 
that includes regional PrEP retention and STI incidence trends from LHD and private providers. 
Remaining gaps in the literature include PrEP-related stigma in rural and suburban areas and 
reasons for PrEP user discontinuation in suburban and rural LHD settings. Barriers to LHD PrEP 
services in rural and suburban areas may differ from urban centers and research on stigma in non-
urban LHDs may benefit uptake and provision of rural and suburban PrEP services. Future research 
on LA PrEP is needed as LA PrEP is an emerging delivery system and poses additional risk of HIV 
viral resistance.16,77 Consideration should also be given to PrEP retention, LA PrEP cost, and 
clinical capacity prior to initiating LA PrEP services in the LHD setting. 
Limitations 
Limitations included the review period of one year after NGHD PrEP service 
implementation as one year is not enough time to appreciate long-term effects of PrEP service 
delivery. The study did not determine presence of causal relationships between PrEP use and STI 
incidence as assessment of temporality or experimental control was not performed. The study only 
included NGHD clinic sites and is therefore not a comprehensive assessment of PrEP user 
population STI incidence because STIs diagnosed at private, non-NGHD clinics were not included 
due to data access limitations. Data obtained in this study was specific to the NGHD (a suburban 
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and rural LHD in the Southeast US) and is possibly not generalizable to other settings although 
generalizability is not essential for a practice program review to be valuable to LHD practice 
program management. The small sample size of the study population and wide confidence interval 
of statistical regression results reduces the meaningfulness of point estimates. The retrospective 
medical record data may also have some variability in documentation between nurse-provider staff, 
and care was taken to select research questions utilizing data that should be consistently present in 
the medical record.  
Possible confounding variables included PrEP user income and insurance status as these 
have been associated with PrEP uptake and retention in PrEP care but were not assessed due to a 
lack of available data. The COVID-19 pandemic also occurred during the study period and is 
expected to have significantly impacted PrEP provision and STI incidence between March and 
June 2020 because the NGHD significantly reduced PrEP and STI service delivery during this time 
due to social distancing and redistribution of resources toward COVID-19 public health response. 
Obtaining qualitative data from NGHD PrEP provider staff and PrEP users would have been ideal 
but could not be performed due to NGHD staffing priorities in response to the ongoing COVID-19 
pandemic and risk of COVID-19 exposure to NGHD PrEP users during the time of data collection. 
Conclusion 
LHDs are critical to the healthcare safety-net, provide key STI prevention services in the 
community, and are well-suited to provide PrEP care to those most at-risk for HIV. This practice-
based study demonstrated the value of ethical decision-making and practice-based research to LHD 
program planning and the need for continuous quality management initiatives in public health 
practice. The Thinking Ethically framework adequately elicited potentially conflicting ethical PrEP 
considerations and was found to be well-suited to LHD PrEP-related decision-making when 
seeking the best course of action. The first year of NGHD PrEP services saw a modest census 
compared to urban PrEP programs and study results indicated possible discrepancies in service 
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delivery between NGHD study sites. LHD PrEP services were considered an opportunity to screen 
for STIs, provide additional health services, and engage vulnerable populations that may otherwise 
forgo medical care. The COVID-19 pandemic impacted STI and PrEP service delivery during the 
study period and follow-up evaluation is needed as NGHD PrEP census is expected to increase 
after the pandemic subsides and the full impact of COVID-19 on program delivery and STI 
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